***Sponsored by LFG Equities Corp

‍

SER founders developed the first-generation of “PEGylated” drugs, which became the standard for delivery of protein drugs and has enabled 30 FDA approved products that have since generated over $140B in cumulative sales

Their lead product candidate, SER-252 for advanced Parkinsons Disease, is anticipated to enter clinical trials in 2025

SER has a Float of Roughly 3.3 Million According to the Leading Charting Site Finviz

Check Out the Investor Presentation Here

‍_________________________

Hello Everyone,

We are in the midst of an incredible market. I was just looking at all of our profiles from September and we have shucked out some significant movers in the past month. I am going to put an update together this week but I encourage you to look at all of the companies that we have profiled over the past month and take a look at how they have performed.

Look at the overall picture and you will see a testament to the strength of the market and not just one particular sector.

For tomorrow we have something that is virtually undiscovered, which is a GREAT catalyst because of the size of the float. According to all of my research, this one has a TINY float of just about 3.3 million according to Finviz. With only 10M outstanding and 47% insider ownership, this one has an extremely favorable structure right now.

Pull up SER right away.

With a focus on next-generation molecules, their work spans diverse central nervous system disorders and beyond.

SER has ongoing collaborations with specialized partners that support the exploration of novel RNA-based medicines targeting vaccine immunology, cancer immunotherapy, and gene therapy.

This forward-thinking approach to drug discovery highlights a commitment to unlocking new possibilities in medicine, making the company well worth closer attention for those interested in emerging therapeutic frontiers.

This one has an interesting story behind it. The founders already did it once. This company was founded in 2007 and was largely funded by the founders and certain investors who followed the team to Serina after the successful exit (via acquisition by Nektar Therapeutics) of the founding team’s prior company, Shearwater Polymers.

At Shearwater, Serina co-founders Dr. Milton Harris and Dr. Michael Bentley developed the first-generation of “PEGylated” drugs. PEG (polyethylene glycol) technology became the standard for delivery of protein drugs and has enabled 30 FDA approved products that have since generated over $140B in cumulative sales. Serina was founded to engineer a next generation polymer therapeutic (our POZ PlatformTM) to address the limitations of PEG and other biocompatible polymer technologies — enabling new treatment paradigms for patients suffering from some of the world’s most challenging diseases.

Serina Therapeutics’ proprietary POZ platform is built on a synthetic, water-soluble, low-viscosity polymer known as poly (2-oxazoline).

During the synthesis process, a precise amount of drug is incorporated onto the polymer backbone using pendant alkyne groups and metal-catalyzed “click chemistry.”

This POZ technology enables enhanced control over drug loading and allows for more precise management of drug release rates.As a result, drugs with narrow therapeutic windows can be engineered to maintain more desirable and stable blood concentrations.

While optimized for small molecules, the platform is also applicable to proteins, aptamers, and other classes of molecules.

POZ Delivers Key Advantages

POZ is engineered to address the limitations of PEG (polyethylene glycol) and other biocompatible polymers – such as immunogenicity, where unlike PEG, POZ does not elicit an immune response or stimulate development of antibodies to the polymer itself.

Enabling Continuous Drug Delivery

Many drugs, for example those used to treat neurological disorders like Parkinson’s, have narrow therapeutic ranges in which they can work safely and efficaciously.

They are often dosed more frequently – resulting in large and frequent fluctuations in drug exposure.

They have to be monitored and dose adjusted with greater frequency, and on an individual basis.

These fluctuations present clinical, compliance and quality of life challenges for many patients.

Administered Subcutaneously, POZ Provides Extended Delivery

Serina is in the process of developing proprietary drugs to treat neurological diseases. Their lead product candidate, SER-252 for advanced Parkinsons Disease, is anticipated to enter clinical trials in 2025. Their current discovery and development work includes a focus on unlocking the potential of cannabinoids and other molecules across a range of CNS indications and beyond. Their POZ platform partners are at the forefront in advancing novel RNA medicines in vaccine immunology, cancer immunoRX, and gene therapy.

Their proprietary POZ platform technology has been designed for programmable, targeted delivery of a broad range of small molecules. The technology has been clinically demonstrated to safely enable continuous drug delivery via a once weekly subcutaneous injection. The POZ platform is customizable, versatile and can be Serina is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and other indications. Serina’s POZ PlatformTM provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs).

The technology is based on a synthetic, water soluble, low viscosity polymer called poly(2-oxazoline). Serina’s POZ technology is engineered to provide greater control in drug loading and more precision in the rate of release of attached drugs delivered via subcutaneous injection. The therapeutic agents in Serina’s product candidates are typically well-understood and marketed drugs that are effective but are limited by pharmacokinetic profiles that can include toxicity, side effects and short half-life. Serina believes that by using POZ technology, drugs with narrow therapeutic windows can be designed to maintain more desirable and stable levels in the blood.

Serina’s POZ platform delivery technology has potential for use across a broad range of payloads and indications. Serina intends to advance additional applications of the POZ platform via out-licensing, co-development, or other partnership arrangements, including the non-exclusive license agreement with Pfizer, Inc. to use Serina’s POZ polymer technology for use in lipid nanoparticle drug (LNP) delivery formulations.

About SER-252 (POZ-apomorphine)

SER 252 is an investigational apomorphine therapy developed with Serina’s POZ platform and designed to provide continuous dopaminergic stimulation (CDS). CDS has been shown to reduce the severity of levodopa-related motor complications (dyskinesia) in Parkinson’s disease. Preclinical studies support the potential of SER 252 to provide CDS without skin reactions. Serina plans to advance SER 252 to clinical testing in 2025.

dosed via IV, SC or IM routes to address a broad range of clinical indications.

Our proprietary POZ platform is based on a synthetic, water soluble, low viscosity polymer called poly (2-oxazoline). During the synthesis steps, a predictable amount of drug is incorporated on the backbone of the polymer using pendant alkyne groups and metal catalyzed “click chemistry”.

POZ technology provides greater control in drug loading, and the rate of release of attached drugs can often be more precisely controlled. Drugs with narrow therapeutic windows can be designed to maintain more desirable and stable levels in the blood. The technology is optimized for small molecules and can also be applied to proteins, aptamers and other classes of molecules.

‍

Their largest shareholder, Juvenescence Ltd., just secured $150 million in Series B financing led by M42, a global tech-enables health company headquartered in Abu Dhabi.

This significant investment and accompanying strategic alliance will accelerate Juvenescence’s mission to develop innovative therapies targeting age-related diseases and extending healthspan. As part of this partnership, Juvenescence and M42 will launch a drug development hub in Abu Dhabi, combining AI-enabled drug discovery with cutting-edge data and clinical infrastructure to speed the development of novel therapeutics.

Juvenescence has been a critical partner to Serina, providing strategic guidance and capital that has helped them advance their POZ Platform™ into the clinic.

RECENT HIGHLIGHTS

• Advancement of SER-270 for Tardive Dyskinesia: In July 2025, Serina announced the advancement of SER-270 (POZ-VMAT2i), a once-weekly injectable therapy for tardive dyskinesia (TD), enabled by the POZ Platform. The program aims to address unment needs in TD treatment, particularly for institutional use and adherence challenges. SER-270 may also be evaluated for Huntington’s disease chorea, a high need indication with limited long-acting injectable (LAI) options.
• Board Appointments: In May 2025, Serina appointed Stephen (Steve) Brannan, M.D. to its Board of Directors. Mr. Brannan brings more than three decades of experience in neuroscience and neuropsychiatry drug development, with a proven track record of leading clinical programs from early development through regulatory approval and commercialization. Dr. Brannan held senior leadership roles at Takeda, Novartis, Cyberonics (now LivaNova), and Eli Lilly, focusing on clinical programs for depression, Alzheimer’s, schizophrenia, and epilepsy. Most recently, as Chief Medical Officer at Karuna Therapeutics, he led the clinical strategy for KarXT (xanomeline–trospium), the first new schizophrenia treatment in over 30 years, which was key in Karuna’s $14 billion acquisition by Bristol Myers Squibb in 2024. This addition strengthens Serina’s Board as the company advances its innovative therapeutic pipeline toward the clinic.
• $5 Million in Funding: In April 2025, Serina secured $5 million from strategic shareholders to support the continued development of SER-252 (POZ-apomorphine), Serina’s lead clinical candidate for Advanced Parkinson’s disease, as the company prepares to initiate a Phase 1 clinical trial in the fourth quarter of 2025.
• Financing via ATM: In April 2025, Serina entered into a Capital on Demand™ Sales Agreement with JonesTrading Institutional Services LLC with respect to an at the market offering program under which the Company may offer and sell $13.3 million of shares of Serina common stock in “at-the-market” (ATM) offerings. As of August 8, 2025, Serina issued 199,562 shares of common stock at a gross average price of $5.95, resulting in net proceeds of $1.2 million.

NEWS‍

Serina Therapeutics Secures Up to $20 Million to Advance Registrational Trial of SER-252 in Parkinson’s Disease

Sep 9, 2025

Serina Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Sep 8, 2025

Serina Therapeutics Announces FDA Feedback Supports Registrational Trial Design of SER-252 in Advanced Parkinson’s Disease under 505(b)(2) NDA Pathway

Aug 25, 2025

Serina Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights

Aug 11, 2025

Serina Therapeutics Advances POZ-VMAT2i into Development for Tardive Dyskinesia (TD)

Jul 29, 2025

Serina Therapeutics to Present at the BTIG Virtual Biotechnology Conference

Jul 28, 2025

Serina Therapeutics Makes Grant to New Employee Under Inducement Plan

Jul 10, 2025

Serina Therapeutics Announces Date for 2025 Annual Stockholders Meeting

Jul 1, 2025

Serina Therapeutics to Present at FORCE Family Office Investor Webinar on June 26, 2025

Jun 23, 2025

UPDATED: Serina Therapeutics Congratulates Juvenescence Ltd. on $76M First Tranche Close of Series B Funding and Strategic Partnership with M42

Jun 17, 2025

Serina Therapeutics Congratulates Juvenescence Ltd. on $150M Series B Funding and Strategic Partnership with M42

Jun 17, 2025

Registration Is Now Open For Tribe Public’s CEO Presentation and Q&A Webinar Event “Is the Beaten Down Biotech Sector the Smartest Bet in Today’s Volatile Market?”

Jun 9, 2025

Serina Therapeutics Appoints Stephen Brannan, M.D. to Board of Directors

May 22, 2025

Serina Therapeutics Makes Grants to New Employees Under Inducement Plan

May 14, 2025

Serina Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights

May 8, 2025

Serina Therapeutics to Present at JonesResearch Virtual CNS Day

Apr 29, 2025

Serina Therapeutics to Present at the 4th LNP Formulation & Process Development Summit

Apr 15, 2025

Serina Therapeutics Secures $5 Million in Funding to Support Advancement of SER-252 into Clinical Development in Advanced Parkinson’s Disease

Apr 8, 2025

Serina Therapeutics to Present at the Jones Healthcare and Technology Innovation Conference

Apr 7, 2025

Serina Therapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights

Mar 24, 2025

MANAGEMENT

‍

Simba Gill, Ph.D.

Executive Chairman

Simba has a wealth of biotech and pharma experience in building companies and transformative platforms as well as developing products, having served in key executive roles at Maxygen, Systemix, Boehringer Mannheim and Celltech over his thirty-year career.  He has served as a partner and advisor at Flagship Pioneering where he was the founding CEO of Evelo Biosciences and as a Venture Partner at TPG where he was Founder CEO of Moksh8 Pharmaceuticals. Simba is currently a board member at Foghorn Therapeutics (NASDAQ – FHTX) and Sensorium Therapeutics. He earned his MBA at INSEAD and received his Ph.D. from King’s College, London.

‍

‍

‍

‍

‍

‍

Steve Ledger

CEO and Director

Steve has served as CEO since March 2024 and CFO from March 2022 to March 2024. He has more than 35 years of experience as an investor, board member, advisor, and in operational roles with early-stage companies. He is a General Partner of Form & Fiction Ventures (FFV), a venture studio that launches and invests in startup and seed stage companies focused on socially responsible initiatives. He has served in investment management roles at Caldwell Sutter Capital, Tamalpais Partners, SF Sentry Securities, Kayne Anderson, and Fidelity Investments. Mr. Ledger received a B.A. in Economics from the University of Connecticut.

‍

‍

‍

‍

‍

‍

‍

‍

‍

‍

Randall

Randall Moreadith, M.D., Ph.D.

Chief Development Officer

Randall has served as Serina’s CDO since March 2024. He served as Serina’s President, CEO, and member of Serina’s board of directors from September 2010 to March 2024. Prior to Serina, Randall served in executive leadership roles including CDO at Nektar Therapeutics, CMO of Cardium Therapeutics, CMO at Renovis, and President / co-Founder of ThromboGenics (now Oxurion). Dr. Moreadith received his M.D. from Duke University and is trained clinically in Internal Medicine and Cardiovascular Diseases. Following his Fellowship in Cardiology at Duke University, he joined the laboratory of Professor Philip Leder where he was a Howard Hughes Medical Institute Fellow in Genetics at Harvard Medical School. Dr. Moreadith received his Ph.D. from Johns Hopkins University.

‍

‍

‍

‍

‍

‍

‍

‍

Greg Curhan

CFO

Greg joined Serina as CFO in August 2024. He has over 35 years of operational, financial, capital markets and strategic advisory experience in various sectors including Investment Banking and Medical Device/Life Sciences. Greg has been a Partner at FLG Partners since 2020. Also since 2020, Greg has served as the CFO for Curevo Vaccines, a private biotech company focused on infectious disease immunology. As CFO, Greg has managed Finance, Legal, HR, and Investor Relations functions for Public and Private companies. He has raised equity and debt capital for both private and public companies, completed numerous successful IPOs, and executed M&A transactions, both acquiring and divesting companies. He has also served in CEO, President and Board of Director capacities. Greg earned a BA degree in Economics from Dartmouth College.

SINCERELY,

DISCLAIMER

THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.

OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF TWENTY THOUSAND USD BY LFG EQUITIES CORP FOR A ONE DAY SER AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.

Sponsored by Interactive Offers, LLC

Nine months ended June 30, 2025 Revenue increased 19% to $58.0 million from $48.7 million.

‍Cemtrex purchased 5,500 SOL ($1Mill) at an average cost of approximately $181 per token – Up About 25% Right Now

Cemtrex Signs Letters of Intent for Two Strategic Acquisitions in Robotics and Aerospace that will Expand Revenues to $100 Million

CHECK OUT THE INVESTOR PRESENTATION HERE

‍_________________________

Hello Everyone,

We are coming off of a profile that just ran from 4.10 to 5.69 in a few sessions. If you have been a member for a while then you already know that is not unusual for that one. There have been a lot of movers lately. The gold company that we have been covering since $6 and as recently as 3 weeks ago when it was around $14 just broke $18 on Friday with no sign of slowing down.

We have another exciting situation with a unique catalyst that could be a potential driver for this one.

Pull up CETX right now on whatever platform you use to research exciting ideas.

First and foremost, this one just implemented a 1 for 15 reverse split last week. This has the float somewhere under 400k according to most of the sources I found including yahoo.

CETX has a few irons in the fire. Right now we see industries face increasing challenges in securing critical infrastructure and maintaining operational efficiency. Traditional security systems are struggling to keep up with modern threats, while industrial sectors require advanced, cost-effective solutions to meet growing demands.

They have revenues and are closing deals:

• $1.2M U.S. county security project
• $1.2M U.S. border security contract
• $1M international deployment in Saudi Arabia
• $800K system for a UK prison facility
• $10.4M contract in December 2024—the largest in their history

This is just this year.

What the market lacks is a comprehensive, scalable security system that integrate AI-driven analytics and seamless cloud-based platforms. Simultaneously, industrial services providers need robust, reliable solutions for complex infrastructure projects that can be delivered with speed and precision.

CETX recognizes these gaps, offering cutting-edge, customizable security solutions and industrial services designed to enhance safety, operational effectiveness, and scalability across diverse sectors, providing much-needed innovation in critical markets.

CETX is a diversified technology company operating in the Security and Industrial sectors. Its Security segment, led by Vicon Industries, provides advanced video management software, high-performance security cameras, and integrated surveillance solutions for enterprise, government, and critical infrastructure. The Industrial segment, through Advanced Industrial Services (AIS), delivers expert rigging, mill-wrighting, process piping, and equipment installation services to manufacturers nationwide. With a focus on innovation, execution, and strategic growth, Cemtrex is committed to enhancing safety, efficiency, and value for its customers and shareholders.

Cemtrex Signs Letters of Intent for Two Strategic Acquisitions in Robotics and Aerospace

New Acquisitions Expected to Drive Total Annual Revenues to $100M and Expand Operating Profit

Hauppauge, NY, Aug. 25, 2025 (GLOBE NEWSWIRE) — Cemtrex Inc. (Nasdaq: CETX), a diversified industrial and technology company, today announced it has signed non-binding letters of intent to acquire two profitable U.S.-based businesses — one in industrial robotics integration and the other in aerospace and defense systems engineering. Combined, the two companies are expected to contribute $15–18 million in annual revenue and $2.5–3 million in operating income on a go forward basis, once closed and integrated.

“These potential acquisitions directly align with our long-term strategy to expand into high-value markets with strong macro tailwinds,” said Saagar Govil, Chairman and CEO. “We believe both businesses bring meaningful scale, margin, and strategic capabilities to the Cemtrex platform.”

The robotics integrator specializes in automation systems for agriculture and construction, expanding Cemtrex’s footprint in industrial automation and complementing its AIS division. The aerospace and defense firm delivers high-reliability communications and electronics systems for government and commercial customers, adding a new strategic vertical with long-term relevance in national security and space infrastructure.

Combined with Cemtrex’s organic growth initiatives, these acquisitions are expected to position the Company to reach $100 million in total revenue and significantly expand the Company’s operating profit. Coming off its strongest operating performance in years, Cemtrex believes these additions, if closed, will further advance its evolution into a focused, cash-generating platform spanning security technology, industrial services & automation, and next generation defense and space systems.

“This marks a meaningful step toward our goal of building a $150 million+ platform with durable earnings power and attractive operating margins,” Govil added. “Not only do these businesses add revenue and income, they bring long-term capabilities in sectors where the next decade of growth will happen.”

Both transactions are in the diligence phase and are subject to definitive agreements and customary closing conditions. Closings are expected to occur in the fourth calendar quarter of 2025. Cemtrex will provide additional updates as material developments occur.

Empowering Growth Through Two Dynamic Subsidiaries: Vicon Industries and Advanced Industrial Services (AIS)

Cemtrex Inc. (NASDAQ: CETX) is at the forefront of redefining the future of security and industrial services. Through its two key subsidiaries— Vicon Industries and Advanced Industrial Services (AIS) — Cemtrex is driving growth and innovation in rapidly expanding markets.

With the increasing global demand for smart security solutions and industrial services, Cemtrex is positioned to capture significant market share. The company’s strategic investments in AI-driven security systems and advanced industrial services are setting the stage for long-term success.

Cemtrex is committed to delivering value to its shareholders by capitalizing on market demand, executing strategic initiatives, and scaling its operations effectively. The company’s innovative products and services are key to unlocking new opportunities and sustaining growth.

As the market continues to evolve, Cemtrex is well-placed to lead with its cutting-edge solutions, unlocking substantial growth potential in the years ahead.

Their technology is impressive.

Check out this video:

CETX just released a shareholder update a few months ago. Here are some of the key points:

Vicon: Momentum, Execution, and the Launch of NEXT

Vicon, our intelligent security division, is performing. Since 2021, we’ve grown revenue from $21 million to a projected $36 million-plus for fiscal year 2025. Gross margins have improved, and our go-to-market engine is accelerating, fueled by the addition of over 60 new resellers this year alone.

Our new modular camera platform, NEXT, began shipping this quarter. It’s our most advanced product line to date—fast to install, AI-powered, visually modern, and designed to meet the complex needs of today’s enterprise and public infrastructure buyers. Early wins, including a $500K school district deployment, are encouraging. We believe this platform has the potential to become the core of Vicon’s next growth phase.

This year, Vicon has delivered:

• $1.2M U.S. county security project
• $1.2M U.S. border security contract
• $1M international deployment in Saudi Arabia
• $800K system for a UK prison facility
• $10.4M contract in December 2024—the largest in our history

These are not pipeline projections—they’re closed deals. Vicon is performing in the market, and we are scaling it with intention.

AIS: Durable Growth with Strategic Ambition

AIS has quietly doubled in size since 2021, with revenue on track to exceed $36 million this year. Demand from food and beverage, packaging, and machinery sectors remains strong, and reshoring trends are creating more opportunity for our services.

We are no longer just a millwright and installation business. We are positioning AIS to become a full-spectrum industrial services platform, one that can handle legacy systems and lead the transition to automated, robotics-enabled manufacturing environments.

To that end, we are in advanced discussions to acquire a Midwest-based robotics integrator. This deal, if completed, would expand our capabilities into robotic workcell design, controls programming, and systems integration, allowing us to better serve manufacturers modernizing their facilities.

Our M&A playbook is disciplined. Our last acquisition was accretive, smoothly integrated, and strengthened our platform. We expect the same results as we scale.

Solana and Blockchain Infrastructure

In July, we allocated $1 million into Solana (SOL) and have since staked our holdings. We view Solana as one of the most structurally sound blockchains in production—high throughput, low latency, and deflationary mechanics hardcoded into the protocol.

This is not a hedge. It’s a strategic bet.

Blockchain infrastructure will become critical to how digital systems establish truth. Whether it’s timestamping surveillance footage, detecting tampering in AI-generated content, or anchoring public safety evidence in immutable ledgers—we believe this technology will be foundational.

Vicon has already begun R&D around blockchain-based video authentication. We intend to move quickly.

Vicon shift to AI Based Analytics solutions & Cloud based VSaaS to drive recurring revenue growth in high gross margin businesses Security segment revenues decreased 7% to $32.0M in FY’24 due to the delay of multiple projects for the segment’s products and services.

CATALYSTS:

• AIS set to expand with strong growth in the Industrial Services market AIS segment revenues increased 39% to $34.8M in FY’24
• Generating margin improvement through increasing prices and reducing overhead where possible Gross margin was 41% in FY’24
• Subsequently announced a $10.4 million Valerus expansion order from a state government corrections customer and three contracts for AIS totaling $11.4 million
• M&A strategy targeting acquisitions in high growth markets with strong ROE and attractive gross margins
• Large, growing, addressable and mature markets in Security, Business, Manufacturing, Government & Industrial
• Revenue for the year ended September 30, 2024, increased 13% to $66.9 million, compared to revenue in the prior year of $59.4 million.
• Revenue for Q4’24 increased 9% to $18.1 million, compared to revenue of $16.6 million for Q4’23.
• Vicon Innovations: Launched NEXT™ Modular Camera System, integrating groundbreaking AI analytics and Hailo-15 edge AI processing, poised to redefine the surveillance industry.

‍

Cemtrex Acquires $1 Million in Solana, Citing Structural Mispricing; Targets $10 Million Crypto Treasury Reserve

Hauppauge, NY, July 31, 2025 (GLOBE NEWSWIRE) —  Cemtrex Inc. (Nasdaq: CETX), a technology company focused on intelligent security systems and industrial services, today announced it has acquired approximately $1 million worth of Solana (SOL) as part of a new digital asset treasury strategy, with the goal of expanding its crypto reserves to $10 million over time.

“Solana is the most underappreciated layer-one blockchain in the world today,” said Saagar Govil, Chairman and CEO of Cemtrex. “It’s already processing more real-world transactions than every other blockchain combined, and it’s not even close. With a hard-coded supply curve and no reliance on fragmented scaling solutions, we believe the market has yet to appreciate what this unlocks in the next 3–5 years.”

Cemtrex purchased 5,500 SOL at an average cost of approximately $181 per token. The company intends to stake its position for on-chain yield and eventually operate its own validator node to directly participate in network security and infrastructure. Cemtrex’s longer term goal is to build a $10 million reserve position across strategic crypto networks, with Solana as the foundation.

Solana is currently processing over 1,000 transactions per second and handled more than 90 billion transactions in June 2025 alone, more than every other L1 and L2 combined. With a burn mechanism tied to usage and a hardcoded inflation schedule set to bottom out at 1.5% by 2028, we believe Solana is uniquely positioned to become a foundational layer for digital trust and settlement.

“This isn’t just a treasury hedge,” Govil added. “It’s a long-duration bet on the most capable, capital-efficient blockchain system in production and one we believe will compound its network advantage faster than the market expects. Over time, we expect Solana to outperform fiat and legacy digital assets on a structural basis.”

Cemtrex is actively exploring ways to integrate blockchain-based technologies into its product lines, including cryptographic video authentication, tamper-proof media verification, and decentralized timestamping through its subsidiary, Vicon.

“This is a long-term strategy grounded in execution. We’re putting capital and infrastructure behind it because we see where this is going,” continued Govil.

‍

Cemtrex’s Vicon Secures $1.2M Follow-On Order for County Security Infrastructure Expansion

Repeat order from major government project highlights accelerating public-sector adoption of Vicon’s video surveillance solutions

Hauppauge, NY, July 08, 2025 (GLOBE NEWSWIRE) — Vicon Industries, a subsidiary of Cemtrex Inc. (Nasdaq: CETX, CETXP) and a leading provider of advanced security and surveillance solutions, today announced that it has secured a follow-on order exceeding $1.2 million to support a major Midwestern county government security upgrade project. The order was placed through a long-standing global systems integration partner.

The scope of the project includes Vicon’s high-performance cameras, recording servers, and Valerus video management software licenses, all deployed to enhance security across multiple county facilities. This order builds on previous deployments and reflects continued customer confidence in Vicon’s reliability, scalability, and system performance. The order is expected to be fulfilled over the coming months and contribute to Vicon’s fiscal 2025 results. Consistent with the terms of the engagement, the names of the client and integration partner are not being disclosed.

“This award reflects the strength of our execution and the trust we’ve earned with key public-sector stakeholders,” said Saagar Govil, Chairman and CEO of Cemtrex. “As municipalities invest in more advanced and unified security platforms, Vicon is increasingly the partner of choice.”

This engagement marks one of Vicon’s largest public-sector wins in recent quarters and reinforces a broader pattern of repeat institutional orders, particularly in government and education verticals. While this deployment leverages Vicon’s established product lines, it comes amid growing market interest in the company’s next-generation offerings, including the award-winning NEXT Modular Sensor System, which has recently been recognized for innovation and design excellence.

“We’re seeing an encouraging pattern take hold,” Govil added. “This order is not an isolated event, it reflects growing momentum from institutional buyers who’ve deployed our systems, seen the results, and are investing further. With an expanding base of repeat government customers, visibility into our long-term growth is becoming clearer.”

Strategic Outlook

This order is further validation of Cemtrex’s ongoing strategy of transforming Vicon from a legacy camera business into a modern surveillance technology platform. The Company’s emphasis on modular design, AI-enhanced analytics, and public-sector readiness is translating into real-world traction, and into contracts with repeat customers executing multi-year infrastructure upgrades.

“We’ve spent the past several years repositioning Vicon for long-term success, and orders like this reflect that transformation taking hold,” said Govil. “We’re executing against a clear strategy, focused on delivering differentiated solutions to institutional customers, and the results are starting to materialize across our pipeline.”

Following recent industry awards, increased sales velocity, and a growing pipeline of institutional projects, Vicon is positioned to deliver meaningful year-over-year growth in fiscal 2025 and beyond.

‍

NEWS

Cemtrex Signs Letters of Intent for Two Strategic Acquisitions in Robotics and Aerospace

Aug 25, 2025

Cemtrex Reports Results for Third Quarter Fiscal 2025

Aug 14, 2025

Cemtrex Highlights $1.3 Million in Notable New Contracts in Past Week Across Security and Industrial Divisions, Reinforces FY26 Growth Outlook

Aug 13, 2025

Cemtrex Issues Shareholder Update Highlighting Growth Across Vicon and AIS Divisions, Strategic Initiatives in Blockchain and Automation

Aug 1, 2025

Cemtrex Acquires $1 Million in Solana, Citing Structural Mispricing; Targets $10 Million Crypto Treasury Reserve

Jul 31, 2025

Cemtrex’s Vicon Developing Blockchain-Based Video Integrity Layer to Combat Deepfakes and Evidence Tampering

Jul 29, 2025

Cemtrex Wins $500K+ Order for NEXT Modular Camera System From Major School District in Kentucky

Jul 10, 2025

Cemtrex’s Vicon Secures $1.2M Follow-On Order for County Security Infrastructure Expansion

Jul 8, 2025

Cemtrex’s Vicon NEXT Camera Wins Multiple Industry Awards, Signaling Commercial Momentum and Category Leadership

Jun 26, 2025

Cemtrex Accelerates Growth Strategy After Strong First Half with Targeted Acquisitions

Jun 12, 2025

Cemtrex Regains Compliance with NASDAQ Stockholders’ Equity Requirement

Jun 9, 2025

Cemtrex’s Vicon Expands Leadership in UK Prison Security Market with New Wave of System Orders

Jun 2, 2025

Cemtrex, Inc. Announces Closing of $1.25 Million Underwritten Public Offering

May 29, 2025

Cemtrex, Inc. Announces Pricing of $1.25 Million Underwritten Public Offering

May 28, 2025

Cemtrex, Inc. Announces Launch of Proposed Public Offering

May 27, 2025

Cemtrex Reports Second Quarter Fiscal Year 2025 Financial Results

May 15, 2025

Cemtrex’s Vicon Secures Prestigious STQC Certification, Strengthening its Position in High-Growth Indian Market

May 12, 2025

Cemtrex Secures $1M Security Technology Order from Major Middle Eastern Media Group

May 7, 2025

Cemtrex’s Vicon Subsidiary Secures $1.2M Order for Border Protection Deployment in Texas

Feb 18, 2025

Cemtrex Reports First Quarter Fiscal Year 2025 Financial Results

Feb 14, 2025

‍

‍

SINCERELY,

DISCLAIMER

THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.

OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF TWENTY THOUSAND USD BY INTERACTIVE OFFERS LLC FOR A ONE DAY CETX AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.

***Sponsored by Primetime Profiles, LLC

KULR Technology Group Launches Six New COTS K1S CubeSat Batteries to Expand Existing Portfolio in Space Power Systems

KULR Partners with Amprius and Molicel to Launch KULR ONE Air for Unmanned Aircraft

Revenue in the 2nd Quarter increased 63% to $3.97 million compared to $2.43 million reported same period last year

As of June 30, 2025, the Company had cash and current accounts receivable combined of $24.73 million and 1,021 BTC or roughly $116 Million as of Today

‍

https://fintech.tv/?p=34308&embed=1

______________________________

Hello Everyone,

We’ve got a familiar name returning as our featured profile tomorrow.

Last year, this one delivered the single biggest move we covered, cementing its spot as the undisputed champion of our newsletter in 2024.

At the time, we highlighted it trading near $0.40—before it rocketed past $4.00, an explosive run of more than 1,200% that set the pace for 2025. There is no doubt it was our most covered company of 2025, appearing more than any other ticker.

Since then, the story has evolved, and while the company is no longer the same as when we first introduced it, the new chapter could prove just as interesting.

KULR now sits at the crossroads of energy storage, electrification, and advanced thermal management—three areas experiencing structural tailwinds as industries adapt to higher safety standards and performance demands. Instead of competing in the crowded battery manufacturing race, KULR develops enabling technologies that enhance safety and efficiency, a focus that has earned validation from NASA, defense programs, and Tier-1 commercial partners. With regulatory momentum pushing energy storage toward stricter compliance and with the added scalability of licensing its intellectual property, the company finds itself uniquely positioned within a clean-tech ecosystem that demands both innovation and reliability. Small-cap dynamics still apply, but KULR’s trajectory highlights why it remains a name worth watching.

Another major factor: KULR just consolodated in a 1 for 8 reverse…… reducing the float.

KULR Technology Group, Inc. (NYSE American: KULR) is a Bitcoin First Company that delivers cutting edge energy storage solutions for space, aerospace, and defense by leveraging a foundation of in-house battery design expertise, comprehensive cell and battery testing suite, and battery fabrication and production capabilities. The Company’s holistic offering allows delivery of commercial-off-the-shelf and custom next generation energy storage systems in rapid timelines for a fraction of the cost compared to traditional programs. Since late 2024, KULR has included bitcoin as a primary asset in its treasury program and committed to allocating up to 90% of its excess cash to the acquisition of bitcoin.

KULR just joined Russell 3000® Index marking another important milestone in their growth trajectory and is expected to enhance both their visibility and liquidity among institutional investors, with approximately $10.6T in assets being benchmarked against Russell US indexes. KULR inclusion in the Russell 3000® Index triggers automatic purchasing from index funds and ETFs that track this benchmark, potentially creating meaningful bu∙ying pressure on the stock.

2025 is a transformational year for KULR and the transformation is well on its way. With over a hundred million in ca∙sh and Bitcoin holdings on their balance sheet and virtually no debt, they’re well-capitalized to grow their battery and AI robotics businesses while their capital market activities in the foreseeable future are geared to turbocharge their Bitcoin acquisition strategy, establishing KULR is a pioneer BTC-first Bitcoin treasury company.

What is a BTC-first company? A Bitcoin-first company treats Bitcoin not as a side asset or payment option, but as a core pillar of its identity, strategy, and mission. KULR’s journey of transformation is riding the wave of the greatest digital transformation in human history, intelligence, capital, and energy. Digital transformation of intelligence is AI, digital transformation of capital and energy is Bitcoin.

Recent Highlights

• 
  KULR Technology Group Joins Russell 3000® Index. The Company announced it had joined the broad-market Russell 3000® Index, effective after the United States market opened on June 30, as part of the 2025 Russell indexes reconstitution. The annual reconstitution of the Russell US indexes captures the 4,000 largest US stocks as of April 30, ranking them by total market capitalization. Membership in the Russell 3000® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000® Index as well as the appropriate growth and value style indexes.
• KULR Expands Bitcoin Holdings to 1,021 BTC, Reports 291.2% BTC Yield. The Company announced on July 10th it increased its bitcoin holdings for its Bitcoin Treasury by additional acquisitions of approximately $10 million to reach a total of approximately $101 million in bitcoin acquisitions. The additional bitcoin was acquired at a weighted average price of $108,884 per bitcoin, inclusive of fees and expenses. The Company now holds 1,021 BTC. Year to date, KULR has achieved a BTC Yield of 291.2%, leveraging a combination of surplus cash, its recently announced Coinbase credit facility and its At-The-Market (ATM) equity program to fund purchases. KULR uses “BTC Yield” as a key performance indicator (KPI) for its Bitcoin Treasury Strategy. BTC Yield is calculated as the percentage change period-to-period in the ratio of the Company’s bitcoin holdings to its Assumed Fully Diluted Shares Outstanding. This KPI helps assess the effectiveness of KULR’s bitcoin acquisition strategy in a manner KULR believes drives shareholder value.
• K1S 500 XLT has Been Shipped to Customers as a Very Lightweight and Compact Designs Providing Cutting Edge Energy Storage Solutions at Commercialized Price Tags that Match the Expected Economics of the Growing Private Space Sector. This variation of the K1S platform combines high quality WI37A screened cells with tight packing factors and low mass structural material selections. The design also has direct integration of KULR’s next generation space environment rated KULR BMS (kBMS).
• KULR Reaches 750 PH/s in Bitcoin Mining Operations with Latest Deployment, Aims for 1.25 EH/s by Late Summer. The Company announced the successful deployment of 3,570 Bitmain S19 XP 140T Bitcoin mining machines at facilities located in Asuncion, Paraguay, thereby boosting the Company’s operational capacity to 750 petahash per second (PH/s) across multiple mining locations. This deployment underscores KULR’s dual acquisition strategy of both mining Bitcoin and purchasing it on the open market. By leveraging a “buy-or-mine” flexibility, KULR intends to build its BTC holdings more efficiently rather than relying on a single method of BTC accumulation. KULR continues to scale its mining operations and aims to reach 1.25 EH/s later this summer.
• KULR Announced its Strategic Partnership with German Bionic in April. In June, the 7th Generation Exoskeleton, EXIA, was Released and is Now Actively Being Introduced to Customers Across North America. Early feedback since units became available from the factory in June has been overwhelmingly positive and we remain very positive about the prospects of this technology to support workers engaged in strenuous manual labor.
• K1G Battery for DoD Applications has Successfully Demonstrated a Ballistic Proof Battery Using API Rounds.
• KULR Completed Delivery of a Pressure-Tolerant Subsea Battery to a Key Strategic Partner, Reinforcing the Company’s Leadership in Advanced Energy Solutions for Extreme Environments.
• KULR Technology Group Announces $20 Million Credit Facility with Coinbase. The Company announced it secured a $20 million credit facility with Coinbase Credit, Inc., a subsidiary of Coinbase Global, Inc. The agreement establishes a multi-draw loan facility which the Company intends to use to fund its strategic Bitcoin accumulation goals. Amounts borrowed under the credit facility will be secured by a portion of the Company’s total bitcoin holdings.
• KULR Consolidates Shares as Part of Broader Market Positioning Strategy. The Company announced it completed a 1-for-8 reverse stock split of its outstanding common stock effective for the commencement of trading on June 23, 2025. KULR’s common stock continues to trade on the NYSE-American Market under the symbol “KULR”. The non-compulsory decision to implement this stock split reflects the Company’s aim to optimize market dynamics, broaden investor appeal and accessibility, and align the stock’s trading conditions with the best interests of its investors. The reverse stock split reduced the number of shares of common stock issued and outstanding from approximately 300 million to approximately 40 million.

‍

KULR Partners with Amprius and Molicel to Launch KULR ONE Air for Unmanned Aircraft Systems

Partnership Brings Advanced Unmanned Aircraft Battery Systems to Market in Q4 2025

HOUSTON, Aug. 19, 2025 (GLOBE NEWSWIRE) — KULR Technology Group, Inc. (NYSE American: KULR) (the “Company” or “KULR”), a Bitcoin-Plus Treasury company that builds a portfolio of frontier technology businesses ranging from high performance energy systems to AI Robotics, today announced strategic partnerships with Molicel, a subsidiary of publicly traded Taiwan Cement (TWSE: 1101.TW), and Amprius Technologies (NYSE: AMPX) to power its new KULR ONE Air (K1A) product line — a family of advanced battery systems purpose-built for the rapidly expanding unmanned aircraft systems (UAS) market. Initial sample shipments began in July 2025, with volume production scheduled for Q4 2025. KULR will offer both standard off-the-shelf K1A systems for rapid deployment and customizable configurations to meet specific OEM requirements.

The K1A line integrates KULR’s industry-leading thermal management technologies with Amprius’ ultra-high energy density SiCore® cylindrical battery cells and Molicel’s high-power P50B cells. This innovative combination of industry-proven cell technologies delivers superior safety, extended flight times, and enhanced capabilities to support the evolving needs of next-generation UAS missions.

“Our new K1A product line represents a pivotal step forward in bringing space-proven technologies to the UAS market,” said Michael Mo, CEO of KULR Technology Group. “We’ve built our legacy on delivering energy and thermal solutions for applications where failure is not an option. With K1A, we’re applying that same level of performance and reliability to advanced unmanned aircraft systems, which are slated to become more common in our everyday lives.”

Engineered for Next-Generation Unmanned Systems

Built on KULR’s decade-long heritage in aerospace and defense, including collaborations with NASA, the K1A battery systems are designed for the demanding operational conditions of fixed-wing, rotary, and eVTOL drone platforms.

Key features of the K1A battery line include:

• Lightweight, high-performance lithium-ion chemistries
• Modular, scalable form factors compatible with multiple UAS types
• Rugged, field-ready design for operation in extreme environments

“Amprius’ silicon anode battery technology delivers industry-leading 500 Wh/kg energy density in an ultra-lightweight form factor, key to extending flight time and payload capacity in next-generation drones,” said Dr. Kang Sun, CEO of Amprius Technologies. “Pairing our SiCore cells with KULR’s ONE Air product line brings together performance and safety in one integrated solution for advanced defense and commercial UAS missions.”

Frank So, Executive Vice President of Molicel, added: “This collaboration with KULR reflects our shared focus on performance and reliability in mission-critical applications. Our P50B cells are designed for high power output, exceptional cycle life, and robust thermal stability — ideal for unmanned aerial systems operating in extreme conditions.”

Capitalizing on Explosive Market Growth

According to recent market research, the global drone battery market is projected to grow from $9.5 billion in 2025 to $49.6 billion by 2035, driven by surging demand for autonomous systems in both commercial and defense sectors. KULR’s K1A platform is positioned to capitalize on this growth by offering high-energy-density power solutions optimized for endurance, safety, and mission flexibility.

This announcement comes amid significant policy shifts in U.S. drone strategy. Following executive orders signed by President Donald Trump earlier this summer to boost domestic drone production, Transportation Secretary Sean Duffy recently proposed regulatory reforms that would expand UAS deployment. The proposed rule would eliminate the need for individual flight waivers while mandating onboard collision avoidance systems — paving the way for broader adoption in sectors like agriculture, emergency response, infrastructure inspection, and last-mile delivery.

‍

ULR and AstroForge Partner to Develop Advanced 500Wh Battery Pack for Space Missions

HOUSTON, April 24, 2025 (GLOBE NEWSWIRE) — KULR Technology Group, Inc. (NYSE American: KULR) (the “Company” or “KULR”), a global leader in advanced energy management solutions, today announced a strategic collaboration with AstroForge, an asteroid resource extraction pioneer, to develop a custom 500 watt-hour (Wh) KULR ONE Space (K1S) battery pack. This partnership highlights the surging demand for reliable high-performance battery systems in the growing space battery market, projected to expand from $3.9 billion to $6.35 billion by 2030, according to Virtue Market Research.

The new 500Wh K1S design leverages KULR’s established modules and NASA JSC 20793-compliant architectures to deliver a fast-to-market solution tailored to AstroForge’s mission-critical needs. Built using NASA-approved cells, validated under WI-37 screening processes, the K1S pack showcases KULR’s engineering prowess in optimizing the design for maximum volumetric and gravimetric energy density. Paired with KULR’s advanced Battery Management System, the solution meets AstroForge’s stringent functional, mechanical, and interface requirements while ensuring uncompromised safety and performance in space.

This collaboration builds on KULR’s proven K1S platform — launched as the first commercial-off-the-shelf lithium-ion battery series fully compliant with NASA safety standards — demonstrating its adaptability to the unique challenges of cutting-edge space missions. The result is a scalable high-efficiency energy solution that accelerates deployment and enhances mission reliability.

“This iteration reflects the third design format of the KULR ONE Space architecture and will focus on energy density and reliability,” said Dr. Will Walker, Chief Technology Officer of KULR Technology Group. “From compact CubeSats to complex resource extraction missions, our modular NASA-compliant designs provide the flexibility and performance our partners demand in a constantly evolving space landscape.”

Robyn Ringuette, Chief Operating Officer of AstroForge, highlighted the partnership’s impact: “KULR’s expertise in working with NASA-approved architectures and delivering a customized solution in record time was a game-changer for our program. Their ability to maximize energy density while meeting our exact specifications ensured we could stay on schedule without sacrificing safety or performance, key to achieving our mission objectives.”

The partnership signals a strengthening network of relationships between KULR and trailblazing companies in the space industry, as demand for innovative energy solutions continues to rise. By blending proven technology with agile design capabilities, KULR is solidifying its leadership in the space battery market, empowering customers to succeed in the most demanding environments.

KULR's Bold Bitcoin Move: A Digital Energy Play?$KULR $MSTR $BTC pic.twitter.com/I1YkzdZrtN

— SmallCapVoice (@smallcapvoice) June 9, 2025

‍

KULR Technology Group Launches Six New COTS K1S CubeSat Batteries to Expand Existing Portfolio in Space Power Systems

HOUSTON, Sept. 09, 2025 (GLOBE NEWSWIRE) — KULR Technology Group, Inc. (NYSE American: KULR) (the “Company” or “KULR”), a Bitcoin+ Treasury company that builds a portfolio of frontier technology businesses ranging from high-performance energy systems to AI Robotics, today announced the release of six new commercial off-the-shelf (COTS) versions ranging from 100 to 500Wh of its KULR ONE Space (K1S) CubeSat battery line, designed to meet the evolving needs of customers across the space sector.

The new K1S batteries are the next evolution, built on KULR’s flight-proven space battery heritage, offering customers enhanced flexibility with designs that prioritize safety, weight efficiency, and mission-specific customization.

Versatile Designs to Power Any Mission Profiles

The six new K1S battery models were developed to serve the wide range of demands from CubeSat and small satellite operators. Customers can now choose from:

• Passive Propagation Resistant (PPR) Series – Designed for customers prioritizing maximum safety in orbital and deep-space missions, leveraging KULR’s NASA-proven PPR architecture.
• Lightweight Models – Optimized for customers requiring mass savings to extend payload capacity or achieve tighter orbital injection budgets.
• Customizable Platforms – Configurable platforms that allow tailored designs to meet and exceed missions with unique requirements.

Commitment to Safety and Performance

KULR’s K1S battery line continues to integrate the company’s core thermal management and safety technologies, providing reliable energy storage that has been trusted by NASA, the U.S. Department of Defense, and commercial space pioneers. The introduction of PPR-enabled models ensures compliance with the highest safety standards while still delivering high-performance energy density.

Supporting a Growing Space Ecosystem

With this product release, KULR strengthens its position as a leading provider of next-generation space power solutions. The K1S line provides a modular path to scale, enabling customers—from research institutions to major aerospace primes—to access space-proven technology with faster lead times and cost efficiencies.

The new K1S battery models are immediately available for commercial orders, with production based at KULR’s cutting edge facility in Webster, Texas.

About KULR Technology Group, Inc.KULR Technology Group, Inc. (NYSE American: KULR) is a Bitcoin+ Treasury company that builds a portfolio of frontier technology businesses ranging from high-performance energy systems to AI Robotics. KULR delivers cutting-edge energy storage solutions for space, aerospace, and defense by leveraging a foundation of in-house battery design expertise, comprehensive cell and battery testing suite, and battery fabrication and production capabilities. The Company’s offering allows delivery of commercial-off-the-shelf and custom next-generation energy storage systems in rapid timelines for a fraction of the cost compared to traditional programs. Since late 2024, KULR has included bitcoin as a primary asset in its treasury program and committed to allocating up to 90% of its excess cash to the acquisition of bitcoin.

‍

‍

Evolution of KULR

KULR Expands into High-Growth Robotics Market with German Bionic AI-Powered Exoskeletons for U.S. Workforce

HOUSTON, April 15, 2025 (GLOBE NEWSWIRE) — KULR Technology Group, Inc. (NYSE American: KULR) (the “Company” or “KULR”), a leader in advanced energy management platforms, today announced the launch of a new strategic partnership with German Bionic(“GB”), a leading global robotics company known for its groundbreaking robotic exoskeleton, Apogee ULTRA, to expand into the rapidly growing fields of robotics and artificial intelligence. GB counts global logistics companies, large retailers, hospitals, and major international airports among its customers, including Dachser Intelligent Logistics, GXO, Nuremberg Airport, Canadian Tire, the British consumer electronics retailer Currys, and the Charité Hospital Berlin. According to Spherical Insights, the global wearable robotic exoskeleton market size is expected to reach $41.5 billion by 2033.

The initiative includes the formation of a dedicated business unit, KULR AI & Robotics, aimed at driving innovation and commercialization of affordable and mature robotic solutions to support the US workforce and reshoring of manufacturing. During their EOY and Q4 earnings call, KULR also announced that their website has been updated and relaunched as KULR.ai to reflect this shift and the introduction of the new business unit. The new unit will be led by Josh Steinmann, VP of AI and Robotics.

“This partnership exemplifies our broader strategy to leverage our energy management expertise and become a key enabler of the robotics and AI ecosystem, as these applications demand higher battery performance and more efficient thermal management for their high-performance electronics,” said Michael Mo, CEO of KULR Technology Group. “AI is a critical enabler of robotics, and we’re aggressively focused on this area – through this partnership and other strategic initiatives – to help shape the future of human-machine interface.”

“We are pleased to have KULR as a key partner, joining us in the journey to scale and deliver the world’s strongest data-driven exoskeletons to North America and beyond,” says Armin G. Schmidt, Founder and CEO of German Bionic. “At the core of our innovation is a clear understanding of energy as a fundamental force – something unseen yet essential in driving both progress and human advancement. Our exoskeletons are designed to empower and elevate frontline workers, unlocking their full potential each day. This partnership is the natural unfolding of our mission to infuse the world with greater value, vitality, and purpose.”

The sixth-generation Apogee ULTRA is a proven, in-market solution engineered for large-scale deployment. Apogee ULTRA and anticipated future generations of the exoskeleton can enhance human energy output significantly and materially reduce workplace injuries, driving outsized returns on investment, employee satisfaction and retention, and reduced healthcare costs. This technology has demonstrated success across multiple sectors, including delivery logistics, supply chain solutions, manufacturing, construction, and healthcare.

Key elements of the partnership include a collaborative technology effort to further enhance the capabilities of Apogee ULTRA, the world’s most powerful exoskeleton, focused on performance improvements, AI integration, and increased user adaptability. KULR will also hold exclusive marketing and distribution rights for North America, establishing the Company as the primary provider of GB’s products spanning all industries.

KULR’s expansion into this sector aligns with US strategic priorities to expand domestic manufacturing and industry. The Company aims to become a key player in the next generation of AI-powered, human-centered robotic technologies serving delivery logistics, supply chain solutions, manufacturing, construction, and healthcare. Looking ahead, KULRplans to localize the manufacturing and assembly of future generation exoskeletons within the United States, supporting domestic supply chain resilience, reducing lead times, and enhancing scalability for widespread adoption.

About KULR Technology Group Inc. KULR Technology Group Inc. (NYSE American: KULR) delivers cutting-edge energy storage solutions for space, aerospace, and defense by leveraging a foundation of in-house battery design expertise, comprehensive cell and battery testing suite, and battery fabrication and production capabilities. The Company’s holistic offering allows the delivery of commercial off-the-shelf and custom next-generation energy storage systems in rapid timelines for a fraction of the cost compared to traditional programs. On December 4, 2024, KULR announced that its Board of Directors has agreed to include bitcoin as a primary asset in its treasury program and committed to allocating up to 90% of its surplus cash to the acquisition of bitcoin. For more information, please visit www.KULR.ai.

About German BionicGerman Bionic is a global robotics firm that develops and manufactures smart power suits and other wearable technologies. It was the world’s first company to deliver connected exoskeletons for the workplace, applying self-learning and artificial intelligence to support lifting movements and prevent poor posture, and thereby becoming an intelligent link between humans and machines. The German Bionic smart power suits and wearables protect the health of workers and markedly reduce the risk of accidents and injury to improve work processes. In recognition of this innovative technology, which puts people back at the center of Industry 5.0, German Bionic has received numerous awards including the CES “Best of Innovation” Award, the Fast Company “Innovation by Design Award”, and the “Innovation Champion” Award of the European Investment Bank. German Bionic is headquartered in Germany and the US, with offices in Berlin, Augsburg, Boston and Tokyo. For more information, visit: www.germanbionic.com.

‍

______________

KULR NEWS ‍

KULR Technology Group Launches Six New COTS K1S CubeSat Batteries to Expand Existing Portfolio in Space Power Systems

Sep 9, 2025

KULR to Host Booth at Commercial UAV Expo 2025

Aug 20, 2025

KULR Partners with Amprius and Molicel to Launch KULR ONE Air for Unmanned Aircraft Systems

Aug 19, 2025

KULR Technology Group Reports Second Quarter 2025 Financial Results

Aug 14, 2025

KULR Technology Group Sets Second Quarter 2025 Earnings Call for Thursday, August 14, 2025 at 4:30 p.m. ET

Aug 5, 2025

KULR Expands Bitcoin Holdings to 1,021 BTC, Reports 291.2% BTC Yield

Jul 10, 2025

KULR Reaches 750 PH/s in Bitcoin Mining Operations with Latest Deployment, Aims for 1.25 EH/s by Late Summer

Jul 9, 2025

Bitcoin Acquisitions Booming as Companies Tap into Coinbase Credit Facilities Opportunity

Jul 8, 2025

KULR Technology Group Announces $20 Million Credit Facility with Coinbase

Jul 8, 2025

KULR to Consolidate Shares as Part of Broader Market Positioning Strategy

Jun 13, 2025

KULR Joins “Bitcoin for Corporations” Initiative Led by Strategy™ and Bitcoin Magazine

Jun 9, 2025

KULR Expands Bitcoin Holdings to 800 BTC, Reports 220.2% BTC Yield

May 20, 2025

KULR Technology Group Reports First Quarter 2025 Financial Results

May 15, 2025

KULR Technology Group Sets First Quarter 2025 Earnings Call for Thursday, May 15, 2025 at 4:30 p.m. ET

May 6, 2025

KULR Launches Blockchain to Create Secure and Verifiable Supply Chain

May 1, 2025

KULR and AstroForge Partner to Develop Advanced 500Wh Battery Pack for Space Missions

Apr 24, 2025

KULR Awarded $6.7M by Texas Space Commission to Advance Cold-Temperature KULR ONE Space Battery Platform

Apr 22, 2025

KULR Expands into High-Growth Robotics Market with German Bionic AI-Powered Exoskeletons for U.S. Workforce

Apr 15, 2025

KULR CEO Michael Mo to Speak at Strategy World 2025

Apr 10, 2025

KULR Reports Record Fourth Quarter Revenue and Full-Year 2024 Financial Results

Mar 27, 2025

‍

KULR MANAGEMENT TEAM

MICHAEL MO

CHIEF EXECUTIVE OFFICER

Mr. Mo is a technology entrepreneur and successful investor with over 20 years of experience in technology management, product development, and marketing. From 2007 to 2015, Mr. Mo served as Senior Director of Business Development at Amlogic, Inc. Prior to Amlogic, he was co-founder and CEO of Sympeer Technology, a peer-to-peer network company. Mr. Mo received a Master’s degree in Electrical Engineering from UC Santa Barbara in 1995.

KEITH COCHRAN

PRESIDENT & COO

Mr. Cochran is a value-driven leader offering 25+ years of exceptional high-paced business management and operations expertise. From 1995 to 2019, he worked for world-class EMS, Jabil, Inc. He concluded his 24-year career with Jabil as Sr. Vice President of Global Business Units. Prior to Jabil, Mr. Cochran was Supply Chain Manager for SCI Systems. Mr. Cochran received his Bachelor of Science in Business Operations from DeVry Institute of Technology in 1990.

DR. WILLIAM WALKER

CHIEF TECHNOLOGY OFFICER

Dr. Walker has significant experience in professional and research-related activities focused on thermo-electrochemical testing and analysis of lithium-ion (Li-ion) battery assemblies and related thermal management products designed for space exploration applications. Prior to joining KULR, Dr. Walker was employed by the National Aeronautics and Space Administration (NASA) Johnson Space Center (JSC) where he focused on designing battery assemblies for human spaceflight applications capable of safely mitigating the effects of thermal runaway and preventing cell-to-cell propagation. Dr. Walker received his B.S. in Mechanical Engineering at West Texas A&M University (WTAMU) and Ph.D. in Materials Science and Engineering at the University of Houston (UH).

SIMON WESTBROOK

CHIEF FINANCIAL OFFICER

In 2009, Mr. Westbrook founded Aargo, Inc., a company specializing in financial consulting services to corporations in various tech-related industries. Prior to Aargo, Mr. Westbrook was CFO of Amber Networks, Inc., and the Chief Financial Officer of Sage, Inc. (NASDAQ: SAGI), a Silicon Valley company specializing in flat panel displays. Before Sage, Mr. Westbrook held senior level financial positions at Creative Technology (NASDAQ: CREAF) and Atari Corp (AMEX: ATC). Simon is a Chartered Accountant and holds a Master’s degree in Economics from Trinity College, Cambridge University.

MICHAEL G. CARPENTER

VICE PRESIDENT OF ENGINEERING

Mr. Carpenter was former Director and Safety Officer of Energy Science Laboratories PCM Heatsink Group. He also served as Quality Manager and Facility Security Officer in the Defense Industrial Security Program from 1988 to 1995. Mr. Carpenter received a B.S. in Applied Mechanics from UC San Diego in 1983.

TED KRUPP

VICE PRESIDENT OF SALES AND MARKETING

Mr. Krupp joins KULR with over 22 years of supplying MIL-SPEC computing solutions to U.S. military and intelligence system integrators. Prior to joining KULR, Mr. Krupp served as Vice President of Sales at San Diego based ZMicro, the preferred choice for rugged computing and visualization for deployed and mission critical applications. He expanded ZMicro’s involvement in several platforms, including special operations, ground vehicle systems, tactical datalinks, and next-generation ISR and eventually led ZMicro’s sales department as the company continued to grow in prominence across the Department of Defense and foreign military community. Mr. Krupp completed his undergraduate work in Information Systems at the University of Texas.

ANTONIO MARTINEZ

VICE PRESIDENT OF OPERATIONS

Mr. Martinez joins KULR with over 37 years of leadership and worldwide manufacturing experience in Electronics Manufacturing and Operations. He spent most of his career at Pulse Electronics Corporation in the electronics manufacturing services industry. Most recently he served as Principal Program Manager of Jabil since 2015, managing business operations spanning Quality Assurance Readiness, Large Production Line Transfers, Project Management, Process Improvement with Increased Productivity, and Customer Qualification Support.

SINCERELY,

DISCLAIMER

THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.

OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF FORTY THOUSAND USD BY PRIMETIME PROFILES LLC FOR A TWO DAY KULR AWARENESS CAMPAIGN BEGINNING ON 9/30/25. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.

***Sponsored by LFG Equities Corp.

‍

Kadimastem Shareholders Approved the Merger with NLS Pharmaceutics

Pipeline strength: Over 100 patents in 140+ countries covering CNS, ADHD, cancer fatigue, Parkinson’s, and more

READ THE INVESTOR PRESENTATION HERE

Exciting news! 🎉 The @SECGov has declared effective our Form F-4 for the planned merger with @Kadimastem.

The combined company, NewCelX, will unite cell therapy & small-molecule innovation to tackle #ALS, #Diabetes, & #CNS disorders.https://t.co/KOp6YWfR34 pic.twitter.com/0bBmZfd4fz

— NLS Pharmaceutics (@NLSPharma) September 10, 2025

_________________

Hello Everyone,

We have a past winner back in the cross hairs ahead of Tuesday’s session.

We have been covering this company for over two years now and have put it in front of you on 3-4 occasions, some with tremendous success.

This one has a history of moving and there have been quite a few developments since we last tasked you with researching NLSP.

The story of NLS is rapidly becoming the story of NewcelX: a debt-free, Nasdaq-listed biotech advancing treatments for ALS, diabetes, addiction, and CNS disorders. With strong financing, validated science, and a merger that multiplies potential, the company is positioned at a powerful inflection point.

This isn’t just a cosmetic change—it’s the signal of a new strategy, new growth opportunities, and a sharper focus on the future.

NLSP is a clinical-stage pharmaceutical company developing innovative therapies for patients with rare and complex central nervous system (CNS) disorders — particularly in areas where existing treatments are insufficient or non-existent. Earlier this year they announced a definitive merger agreement with Kadimastem Ltd. (TASE: KDST) (“Kadimastem”), a clinical-stage cell therapy company specializing in “off-the-shelf” allogeneic cell products for neurodegenerative diseases and diabetes.

The merger will create a company with complementary approaches in cell therapy and small molecules, broadening the therapeutic scope in CNS disorders and metabolic diseases.

The merger is significant because it offers a pathway to greater scale, diversification, capital-market access, and potentially higher valuation.

‍Uniting NLS’s small molecule / CNS expertise with Kadimastem’s cell therapy pipeline creates a massive vision for their pipeline and current operations.

One of the benefits of the merger is that the new company with have a more diversified and more compelling pipeline. The merger combines cell therapy (Kadimastem) and small molecule / CNS modalities (NLS). This diversification may reduce dependency on any single program. f one program underperforms, the other’s success may balance downside risk. A richer, stronger pipeline makes the company more attractive to investors, partners and potential acquirers.

Kadimastem willl now have better access to U.S. capital markets and liquidity. This is something that cannot be understated. The U.S. is the biggest market in the world by a long shot. They will undoubtably have a stronger cash runway post-merger.

NLS plans to divest certain legacy assets and distribute proceeds (via CVR) to its existing shareholders. NLS shareholders can potentially receive value from those legacy assets aside from the equity in the new entity.

Kadimastem’s lead assets like AstroRx for ALS, IsletRx for insulin-dependent diabetes have high upside potential if successful in trials.

NLSP also completed some major financing events that will propel them forward through the merger. During the first quarter of 2025, they initially closed two equity financing transactions, resulting in aggregate gross proceeds of $2.5 million, priced at $3.10 and $1.65 per share at a premium to the market share price as of the date of the transactions, representing a premium of 48% and 10%, respectively. They also signed a $25 million equity facility commitment. The potential proceeds from this facility are earmarked to support the merger with Kadimastem Ltd. and the Company’s advance clinical programs.

Since announcing its proposed merger with Kadimastem, NLS Pharmaceutics has raised over $6 million to support both the transaction itself and the combined company’s clinical trials once the merger is complete. The company has also converted all outstanding liabilities into equity, leaving it completely debt-free. These financing moves have not only strengthened the balance sheet but also extended the cash runway, giving NLS the resources to continue advancing its R&D programs while moving forward with the merger execution.

In early 2025, NLS Pharmaceutics reported encouraging preclinical data for AEX-2, further supporting the potential of its dual orexin receptor agonist (DOXA) platform in treating central nervous system disorders. Around the same time Kadimastem, together with iTolerance, successfully completed a Pre-IND meeting with the FDA for its Type 1 Diabetes therapy—an important milestone that adds a significant asset to the future combined entity, NewcelX. By April 2025, additional progress came through Study KO-943, where Mazindol ER demonstrated the ability to significantly reduce fentanyl-induced reward behaviors in animal models. These results serve as meaningful proof-points for both safety and therapeutic potential as the program advances toward next-stage trials.

Looking ahead to the anticipated closing of the merger, the combined company is preparing to advance multiple clinical milestones. These include the launch of a Phase IIa multi-site clinical trial of AstroRx® in ALS, the initiation of a Phase I study of IsletRx for Type 1 diabetes, and the continued preclinical development of AEX-2 and AEX-41 as they progress toward late-stage studies in conditions such as narcolepsy and neurodegeneration.

One of the fastest-growing sectors in global healthcare is ADHD, a market projected to reach $70+ billion by 2032. NLSP’s lead candidate, Mazindol ER, directly addresses this space — and more.

Mazindol ER: A Phase 3-Ready Asset with Broad Potential

Mazindol ER is an extended-release formulation of a well-studied compound with a proven safety profile. It’s Phase 3-ready for both:
• Attention Deficit Hyperactivity Disorder (ADHD)
• Narcolepsy and Excessive Daytime Sleepiness (EDS)

With Orphan Drug Designation in both the U.S. and Europe, and a strong Phase 2 data package in hand, Mazindol ER is positioned to move swiftly through the regulatory pipeline. The upcoming AMAZE Phase 3 trial will focus on adult patients with narcolepsy, a $4.5 billion market projected by 2027.

⸻

^{Strategic Expansion: Tackling the Opioid Crisis}

In a significant step beyond CNS and sleep disorders, NLS also holds a U.S. patent for the use of Mazindol ER in treating opioid use disorder, including heroin and fentanyl addiction. A preclinical study targeting fentanyl addiction is underway and expected to yield promising results.

This positions NLSP within the $5 billion opioid addiction treatment market, a high-priority area for the U.S. government and public health institutions. With fentanyl-related overdoses now the leading cause of drug-related deaths in the U.S., the need for non-opioid alternatives has never been greater. Mazindol ER’s unique pharmacological profile — modulating dopaminergic and noradrenergic pathways without being addictive — makes it a compelling candidate in this space.

NLS isn’t just riding the momentum of emerging markets in ADHD and sleep disorders — they’re building long-term value through intelligent pipeline development, strategic IP, and a focus on real-world, unmet clinical needs. And now, with its entrance into the fight against opioid addiction, NLSP adds a compelling new dimension to its mission.

In a market that punishes hype and rewards substance, NLSP is on the path to quietly execute.

‍

‍

PIPELINE

NLS Pharmaceutics CEO Issues Letter to Shareholders

Dear Shareholders,

We are delighted to share a summary of NLS Pharmaceutics’ achieved milestones since the fourth quarter of 2024. Here’s a snapshot of our progress and what lies ahead:

1. Completion of Major Financing Events

• During the first quarter of 2025, we initially closed two equity financing transactions, resulting in aggregate gross proceeds of $2.5 million, priced at $3.10 and $1.65 per share at a premium to the market share price as of the date of the transactions, representing a premium of 48% and 10%, respectively.
• In addition, we signed a $25 million equity facility commitment. The potential proceeds from this facility are earmarked to support the merger with Kadimastem Ltd. (TASE: KDST). (“Kadimastem”) and the Company’s advance clinical programs.

Since we first announced the proposed merger with Kadimastem, we have raised more than $6 million in the aggregate to support the pending transaction and the combined company’s clinical trials post-merger. Moreover, we have converted all of the Company’s outstanding liabilities into equity, reflecting a strong balance sheet of a company free of debt.  These financing events have not only strengthened our balance sheet, but have extended our cash runway, enabling us to pursue continued research & development efforts and proceed with the execution of the merger.

2. Positive Clinical and Preclinical Developments

• In February 2025, we announced encouraging preclinical data for AEX–2, further validating our dual orexin receptor agonist platform (“DOXA”) for central nervous systems (“CNS”) disorders.
• In February 2025, we announced that Kadimastem and iTolerance successfully completed a Pre-IND Meeting with the U.S. Food and Drug Administration (FDA) for its Type 1 Diabetes Treatment, representing a significant asset for the merged company, NewcelX.
• In April 2025, positive results from Study KO–943 revealed that Mazindol ER significantly reduced fentanyl–induced reward behaviors in animal models. These results represent important proof–points for both safety and therapeutic potential as we prepare for next–stage trials.

3. Merger with Kadimastem — Strategic Synergy in Action

• In January 2025, following the approval by the board of directors of NLS and Kadimastem, Kadimastem’s shareholders overwhelmingly approved the merger, a critical step in closing the merger and in bringing together the complementary strengths of Kadimastem and NLS.
• Amendments to the Registration Statements on Form F–4 were filed, paving the way for the final NLS shareholder vote.

Today, the merger process is progressing. We target completing the merger in early Q3 2025, subject to requirements set forth by all regulatory agents.

Ronen Twito, Executive Chairman and Chief Executive Officer of Kadimastem, said, “We are excited about the upcoming merger, which aligns with our strategic goals and will enable us to provide comprehensive therapeutic options for patients. By joining forces, we can better serve those with diabetes and combat its complexity. This merger demonstrates a commitment to innovation, patient care, and long-term value. Together, we aim to improve the lives of diabetics and patients with related conditions. We are committed to ensuring a smooth integration process as we move forward, following the completion of the merger. In addition to the equity investment, we believe the committed equity facility agreement of $25 million will enhance the combined company’s balance sheet and could provide flexibility to support future pipeline development.”

4. What the Combined Company Will Look Like

• The combined entity will be named NewcelX and intends to be a Nasdaq–listed clinical–stage biotech with a robust pipeline spanning neurodegenerative disease (AstroRx® for amyotrophic lateral sclerosis (“ALS”) in a Phase IIa stage), diabetes (IsletRx), and CNS disorders via the DOXA platform.
• Shareholders are expected to continue to benefit from our legacy assets—notably Mazindol ER—through contingent value rights subject to potential future sales.

5. Looking AheadAs we approach the anticipated closing of the merger, we are preparing to rapidly initiate:

• Phase IIa multi–site clinical trial for AstroRx®, targeting ALS.
• Phase I study for IsletRx in Type I diabetes.
• Continued preclinical progression of AEX–2/AEX–41 toward late–stage development (e.g., narcolepsy, neurodegeneration).

Our anticipated merger with Kadimastem is expected to mark a transformational pivot—uniting our proprietary DOXA platform and the cell–therapy assets under one roof. With a fortified capital structure, and a unified board guiding our research and development direction, we are strategically positioned for meaningful value creation.

In ConclusionThanks to your trust and resilience, NLS stands on the edge of a powerful new chapter. We anticipate the closing of the merger to occur in the near future, followed by an energized integration phase and accelerated clinical momentum.

Thank you for your enduring support. Together, we will accelerate development, diversify our pipeline, and enhance long-term shareholder value.

With optimism,Alexander C. ZwyerChief Executive OfficerNLS Pharmaceutics (NASDAQ: NLSP)

About NLS Pharmaceutics Ltd.

NLS is a global development-stage biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders who have unmet medical needs. Headquartered in Switzerland and founded in 2015, NLS is led by an experienced management team with a track record of developing and commercializing product candidates. For more information, please visit www.nlspharma.com.

About Kadimastem

Kadimastem is a clinical stage cell therapy company, developing “off-the-shelf”, allogeneic, proprietary cell products based on its technology platform for the expansion and differentiation of Human Embryonic Stem Cells (hESCs) into functional cells. AstroRx®, the company’s lead product, is an astrocyte cell therapy in clinical development for the treatment for ALS and in pre-clinical studies for other neurodegenerative indications.

IsletRx is the company’s treatment for diabetes. IsletRx is comprised of functional pancreatic islet cells producing and releasing insulin and glucagon, intended to treat and potentially cure patients with insulin-dependent diabetes. Kadimastem was founded by Professor Michel Revel, Chief Scientific Officer of Kadimastem and Professor Emeritus of Molecular Genetics at the Weizmann Institute of Science. Professor Revel received the Israel Prize for the invention and development of Rebif®, a multiple sclerosis blockbuster drug sold worldwide. Kadimastem is traded on the Tel Aviv Stock Exchange (TASE: KDST).

MANAGEMENT TEAM

Ronen Twito CPA | Executive Chairman Nominee and CEO

Mr. Ronen Twito serves as Executive Chairman and CEO of Kadimastem, having joined the company in December 2020. Under his leadership, he successfully repositioned the company’s strategic direction, establishing Kadimastem as an emerging global leader in the cell therapy industry. Mr. Twito brings over two decades of executive leadership experience in the biotech and high-tech sectors, with a distinguished track record of driving corporate growth and maximizing shareholder value across both Nasdaq and Tel Aviv Stock Exchange listed companies.

Throughout his career, Mr. Twito has demonstrated exceptional expertise in corporate finance and strategic leadership, successfully orchestrating multiple IPOs, follow-on offerings, and high-value strategic licensing and collaboration agreements within the clinical biotech sector. His executive tenure includes pivotal roles as Deputy CEO and CFO at XTL Biopharmaceuticals (XTLB), Chief Executive Officer at Intercure Ltd, Executive Chairman at Bubbles Intergroup Ltd (BBLS), Deputy CEO and CFO at Cellect Biotechnology (APOP), External Director at MTS (MTSL), and VP Finance and Head of Israel Operations at BioBlast Pharma (ORPN). Earlier in his career, he served as Corporate Finance Director at LeadCom Integrated Solutions, a global company traded on London’s AIM market, and as Manager at Ernst & Young.

Mr. Twito is a Certified Public Accountant (CPA) in Israel and holds a bachelor’s degree in Business Administration and Accounting. He maintains active membership in the Institute of Certified Public Accountants in Israel.

Prof‭. ‬Michel Revel‭, ‬MD‭, ‬PhD‭ ‬ | Chief Scientist Officer and Director Nominee

Prof‭. ‬Revel is Professor Emeritus of Molecular Genetics at the Weizmann Institute of Science‭. ‬His research on Interferon‭, ‬its mechanisms of action and the isolation of the human Interferon-beta gene‭, ‬have led to the development of Interferon-beta therapy for the treatment of multiple sclerosis‭, ‬Rebif®‭, ‬Blockbuster drug marketed worldwide‭.‬

In recent years‭, ‬Prof‭. ‬Revel’s laboratory focused on hESC and succeeded to produce nerve myelinating cells that‭, ‬when transplanted in myelin-deficient animals‭, ‬have regenerated the myelin coating‭. ‬These studies contributed to the development of a suspension culture technology for hESC which can then be used to produce differentiated human cells such as insulin-producing pancreatic‭ ‬beta cells and nerve myelinating cells‭.‬

Alongside his research and development activity‭, ‬Prof‭. ‬Revel is deeply involved in the ethics of science and biotechnology‭, ‬and‭ ‬served as chairman of the Israel National Bioethics Council‭, ‬and was a member of the International Bioethics Committee of UNESCO‭.‬

Prof‭. ‬Revel was the recipient of the Israel Prize for medical research‭, ‬the EMET Prize for biotechnology‭, ‬and is a member of the‭ ‬Israel Academy of Science and Humanities‭. ‬He has been a member of Israel’s National Committee for Biotechnology‭, ‬serving for three years as its chairman‭.‬

CLICK HERE FOR Prof. Michel Revel full CURRICULUM VITAE

Kfir Molakandov PhD  | VP Research and Development

Dr. Kfir Molakandov started his academic career in developmental biology with Prof. Sarah Ferber’s research on transdifferentiation of liver to the pancreas.

During his PhD, he trained at the Gene Therapy Center, Alabama, USA, and specialized in adenoviral vectors construction, modifications and purification. Following the completion of his thesis, Dr. Molakandov joined Kadimastem.

He leads the team that is developing cell-therapy for diabetes using Pluripotent Stem Cells as the cell source. His team has dedicated the last few years in developing a large scale robust protocol for generating islet cells in high quantities and high quality.

Currently, we have finalized the production process that includes a full characterization of the different stages of differentiation using molecular tools and physiological parameters.

Accordingly, we are now moving towards the clinical application of this technology, aiming to bring these therapeutic cells to clinical trials.

Ariel Revel, MD, | Director of Medical Affairs

Prof. Ariel Revel, MD, is a professor of medicine at Tel Aviv University and a Visiting Professor at Oxford University in the UK and Stanford University in California. He is among Israel’s leading specialists in gynecology and obstetrics and has for many years been involved in IVF and minimally invasive surgery.

Ariel Revel served as a battalion and brigade physician, and raised his family in Nataf. He volunteers with Etgarim, where he kayaks and rides tandem bikes with children and teens with disabilities, and with Physicians for Human Rights, as a physician at the clinic for status-less individuals in Jaffa.

He is a an important figure on the medical landscape, and this together with his impressive knowledge and many years of experience has produced one of the most fascinating books published in recent years in Israel.

​Ariel at Kadimastem is responsible for the following areas

1) To represent the surgical and medical aspects of islet transplantation for patients with diabetes.

2) To promote to medical doctors that cell therapy is the future of medicine. To improve and perhaps cure neurodegenerative diseases such as ALS.

3) Present to general public and potential inventors the potential of human embryonic stem cells to produce clinical level adult cells to cure Diabetes, Glaucoma  and Traumatic Spinal Cord Injuries

NEWS

Kadimastem and NLS Pharmaceutics Announce Effectiveness of SEC Registration Statement in Connection with Proposed Merger

Sep 10, 2025

NLS Pharmaceutics and Kadimastem announce a Hong Kong Patent Covering Cell-Selection and Enrichment Technology for IsletRx for Diabetes Patients

Sep 4, 2025

NLS Pharmaceutics Highlights Continued Progress in iTOL-102 Diabetes Program as BIRD Foundation Approves Additional Milestone Payment to Kadimastem and iTolerance for Continued Co-Development of Type 1 Diabetes Cell Therapy

Jul 17, 2025

NLS Pharmaceutics and Kadimastem Announce Pricing and Closing of $1 Million Equity Financing

Jun 30, 2025

NLS Pharmaceutics CEO Issues Letter to Shareholders

Jun 16, 2025

NLS Pharmaceutics to Present New Data on the Dual Efficacy of Mazindol ER in Fentanyl Reward and Withdrawal at the 2025 ASCP Annual Meeting

May 21, 2025

NLS Pharmaceutics Announces Positive Results from Study KO-943 Demonstrating Mazindol Reduces Fentanyl-Induced Reward in Animal Models

Apr 15, 2025

NLS Pharmaceutics and Kadimastem Announces Up to $3 Million Equity Financing and $25 Million Equity Facility Agreement

Mar 31, 2025

NLS Pharmaceutics CEO Issues Letter to Shareholders

Mar 10, 2025

NLS Pharmaceutics Announces New Preclinical Data for AEX-2, Expanding the Therapeutic Potential of its Non-Sulfonamide Dual Orexin Receptor Agonist Platform

Feb 27, 2025

Kadimastem and iTolerance Successfully Complete Pre-IND Meeting with the FDA for its Type 1 Diabetes Treatment

Feb 25, 2025

Kadimastem and iTolerance Successfully Complete Pre-IND Meeting with the FDA for its Type 1 Diabetes Treatment

Feb 25, 2025

NLS Pharmaceutics and Kadimastem Unveil Multi-Target Approach to Diabetes, Expanding Beyond GLP-1 Therapies

Feb 10, 2025

Kadimastem Shareholders Approved the Merger with NLS Pharmaceutics

Jan 31, 2025

NLS Pharmaceutics Announces the Submission of Three Research Abstracts to the 2025 ASCP Annual Meeting

Jan 30, 2025

NLS Pharmaceutics Announces the Launch of a Preclinical Program for Mazindol ER in the Treatment of Fentanyl Dependence

Jan 28, 2025

Kadimastem Calls for a Special General Meeting of Shareholders to Approve the Merger with NLS

Jan 16, 2025

NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce the Initial Closing of $500,000 of the Previously Announced $1 Million Fundraising by NLS Following its Extraordinary General Meeting at a Share Price of $3.10, Representing 48% Above the Market Shar…

Jan 8, 2025

NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Filing of F-4 Registration Statement with the SEC Ahead of Proposed Merger

Dec 30, 2024

NLS Pharmaceutics and Kadimastem Announce the Submission of a Request by Kadimastem and iTolerance, Inc. for an FDA Pre-IND Meeting for an Innovative Breakthrough Type 1 Diabetes Treatment

Dec 19, 2024

SINCERELY,

DISCLAIMER

THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.

OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF SEVENTEEN THOUSAND FIVE HUNDRED USD BY LFG EQUITIES CORP FOR A ONE DAY NLSP AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.

***Sponsored by LFG Equities Corp

Knightscope has a Big Warchest of $24.2 Million Cash on Hand as of August 8, 2025

Knightscope on Capitol Hill Briefs U.S. Congress on National Robotics Strategy

New Business Surges Past $7 Million With Broader Market Reach

________________________

‍‍Hello Everyone,

September has been an incredibly busy month for us. We took a look at a lot of companies that operate in many different sectors. We anticipate more of the same in October as we already have several companies lined up that we are going to put in front of you this week.

First and foremost we want you to take a look at Knightscope (NASDAQ:KSCP) immediately.

This AI robotics company is already on the move, literally.

With millions in revenue and over 4 million hours of autonomous operations, it’s been deployed coast-to-coast in government buildings, hospitals, airports, universities, and even law enforcement agencies.

The future isn’t coming. It’s already patrolling … autonomously.

Knightscope CEO Briefs U.S. Congress

We believe it is for the first time in history that an Autonomous Security Robot (ASR) was present for a Congressional briefing – but you can watch the whole thing here.  There is a lot of activity on Capitol Hill to get a National Robotics Strategy in place to secure the future of Physical AI for the United States. 

Knightscope’s Explosive Growth: $7M+ in New Deals

Knightscope’s rise is unmistakable. Since April 2025, the company has clinched over $7 million in new contracts and renewals, proving that demand for its Autonomous Security Robots and Emergency Communication Devices is accelerating nationwide.

• $2M+ in fresh sales and renewals across key sectors by early April.
• $1.2M+ more from expanded government and enterprise agreements in late April.
• $1M+ deal wins in June from new public and private sector projects.
• $1M+ again in July with soaring bookings in emergency communications and robot deployments.
• $1M+ again in July as Knightscope Closes more New Sales Wins, Renewals & Expansions
• $1M+ in Early September from contract renewals, expansions and newly won sales.

These are locked-in contracts and real deployments, not just prospects. Knightscope’s solutions are rolling out across cities, hospitals, and campuses as safety concerns and automation needs grow.

There are several other recent highlights to look at besides the strong revenues pouring in:

• Repayment of Senior Secured Facility Related to Dilutive Warrants – In a significant step toward simplifying its capital structure and eliminating shareholder dilution risk, as of June 30, 2025, Knightscope has fully repaid its $3.0 million senior secured promissory note, eliminating the debt and strengthening the Company’s balance sheet.
• New Headquarters – Knightscope signed a lease for a 33,355 square-foot facility in Sunnyvale, California, more than doubling its footprint – and has now moved into the expanded space will serve as the Company’s new headquarters and hub for engineering, manufacturing, and client support.  We got a sneak peek at what it is planned to look like!

• Recurring Revenue Growth – Service revenue rose 7% year-over-year in Q2, supported by increased deployments within the Company’s top client accounts.
• Innovation Investment – Continued strategic R&D investment in the upcoming K7 platform, autonomy, AI-powered analytics and a new generation of products. Look for some new products to hit production in 2026.

Wall Street Analyst Forecasts

As of September 24, 2025, Knightscope (NASDAQ: KSCP) carries a market capitalization of just $58 million. That is a level so small that most institutions cannot even take a position.

And yet, Wall Street’s sharpest analysts are beginning to catch on.

• H.C. Wainwright has set a $12 target, pointing to more than 110% upside.
• Lake Street is calling for gains of over 40% with an $8 price target.
• Ascendiant has gone even further with a $26 target, suggesting a climb of more than 355%

These are not speculative voices on the fringe. These are respected research desks issuing repeated Buy ratings with conviction.

The remarkable part is that despite these forecasts, the broader market still has not noticed. That leaves a gap between the current $58 million valuation and the potential outlined by Wall Street. Given that the valuation is significantly lower than the $200+ million in invested capital is another indicator to consider. 

This is the type of disconnect that rarely lasts. Once larger investors begin to move in, the window can close very quickly.

Compared to its peers, the company stands out as a powerful, ground-floor opportunity that’s vastly undervalued. As momentum builds and more industry experts take notice, Knightscope is positioned to deliver potentially extraordinary long-term upside for early investors.

The Growth Curve Could Be Just Getting Started

If there’s one thing Wall Street consistently underestimates, it’s early-stage companies with real technology, real customers, and a recurring revenue model baked in from day one.

That’s exactly what we’re looking at with KSCP.

This isn’t some prototype company hoping to generate sales someday.

Knightscope is already in motion, earning revenue, scaling deployments, and building predictable income streams through its Machine-as-a-Service (MaaS) business model.

And yet…

Although the company reported over $24 million of cash on hand – a record for Knightscope – that’s a rounding error compared to today’s AI titans. 

But it’s also where opportunity lives.

Just look at Nvidia (NASDAQ:NVDA). A decade ago, it was best known for gaming chips. Today? It’s the backbone of the AI revolution.

In just the past five years, NVDA stock surged more than 1,350% as investors caught on to its role in enabling next-gen intelligence.

Now ask yourself: What happens when the world catches up to the fact that Knightscope is doing for physical security what Nvidia did for AI computation?

In 2025 alone, KSCP:

• Locked in over $7 million in new contracts, renewals and expansions
• Expanded into universities, airports, and government agencies
• Secured a new 33,000 sq ft Silicon Valley headquarters to support manufacturing, engineering, and deployment

And this is just the start.

The broader trend is impossible to ignore.

In the US, there’s one human security officer for approximately 400 people. Labor shortages and rising costs are only compounding the problem. Meanwhile, crime and public safety concerns are escalating across the board.

That’s where KSCP steps in, offering round-the-clock AI protection, remotely managed, highly scalable, and now, federally certified.

As government contracts ramp up and private sector demand grows, Knightscope’s recurring revenue model could start compounding rapidly turning a tiny-cap robotics firm into one of the most important players in physical AI.

This isn’t theoretical anymore.

The infrastructure is built. The machines are online. And the revenue is already flowing.

KSCP is trading at a sub $60 million market cap with only 9.85 million shares outstanding.

That’s a tiny valuation and a low float for a company with:

• Government clearance to operate across federal agencies (via FedRAMP ATO)
• A partnership with Verizon Frontline to power real-time, first-responder-grade connectivity
• Inked a Phase 1 contract with the U.S. Air Force
• A new 33,000 sq ft Silicon Valley headquarters built to scale operations nationwide
• And a recurring revenue model through its Machine-as-a-Service (MaaS) platform; recurring revenue for the recurring societal problem of crime.

Insiders are aligned. CEO William Santana Li personally owns 223,924 shares, and institutional players like Vanguard, Geode Capital, and State Street are already on the books.

If you believe AI is transforming every corner of modern life from finance to medicine, ask yourself this:

Who’s leading the charge in physical security?

Knightscope may be the answer Wall Street hasn’t fully priced in… yet.‍

The Robots Are Coming To Washington And They’ve Got Clearance To Operate

When the U.S. federal government green-lights your tech for secure deployment across its agencies, it’s a signal worth paying attention to.

KSCP has earned that distinction. Through the support of the U.S. Department of Veterans Affairs, Knightscope’s flagship K5 Autonomous Security Robot was awarded a FedRAMP Authority to Operate (ATO)17.  One of the most difficult certifications to achieve in the federal cybersecurity world.

Translation?

Knightscope’s AI-powered security systems are now approved for deployment across the entire U.S. federal government.

That alone could be a game-changer for this fast-moving robotics firm. Shortly after securing FedRAMP Authority to Operate, Knightscope reached a new level of federal credibility:

The U.S. Air Force selected Knightscope for a prestigious Phase I SBIR contract through AFWERX, its primary innovation arm. The initiative tasks Knightscope with evaluating and recommending upgrades for security protocols at Air Force installations nationwide.

Knightscope’s Autonomous Security Robots (ASRs) will be assessed for both perimeter and internal defense applications.

The project focuses on deploying robots equipped with real-time anomaly detection, 24/7 autonomous patrol capabilities, and advanced AI-driven threat analysis, features that are purpose-built to enhance base security and operational efficiency.

AFWERX isn’t just a collaborator; it’s the Department of the Air Force’s engine for bringing cutting-edge technologies into critical defense operations. Landing this contract marks a powerful endorsement of Knightscope’s tech and sets the stage for broader federal and military adoption

And behind it all is a powerful ally: Verizon.

Knightscope’s K5 GOV robots are deployed with priority access on Verizon’s Frontline network, giving them the same resilient, first-responder-grade connectivity relied on by emergency crews and public safety agencies across the country.

That means continuous surveillance, instant threat alerts, and one-touch access to fire, police, and EMS… even in mission-critical black zones.

This type of government-grade, always-on security solution couldn’t be more timely.

Demand for scalable, autonomous security is rising fast across the U.S. From schools and airports to transit hubs and federal sites, critical locations are actively searching for reliable, AI-powered solutions that don’t call in sick, take breaks, or miss a shift.

Knightscope, Inc. (NASDAQ:KSCP) is already trusted by institutions like:

• The Port Authority of New York and New Jersey
• Penn Entertainment
• University in Tennessee

And recent traction backs it up.

Knightscope, Inc. (NASDAQ:KSCP) has:

• Secured over $7 million in new business, featuring key client renewals and broader device rollouts
• Sold 70+ Emergency Communication Devices (ECDs) and six‑figure commitments for 11 Autonomous Security Robots (ASRs)
• Reported a 4% YoY increase in service revenue, now totaling $7.5 million for FY 2024
• Launched upgrades to the K5 ASR, improving its autonomous navigation and machine-learning threat detection

Knightscope Joins Forces with Palantir to Advance Public Safety

Joins FedStart Program to Expand Autonomous Security in U.S. Federal Agencies

SUNNYVALE, Calif.–(BUSINESS WIRE)– Knightscope, Inc. (NASDAQ: KSCP), a leader in developing autonomous security robots and artificial intelligence technologies, today announced it has signed a two-year agreement with Palantir Technologies Inc. (NASDAQ: PLTR), joining Palantir’s FedStart program to accelerate the Company’s entry into the U.S. federal marketplace.

‍The collaboration provides Knightscope with an accelerated pathway to FedRAMP High and DoD Impact Level 5 accredited environment, comprehensive onboarding services, and direct Authority to Operate (ATO) support. These capabilities are essential to deploying AI-driven public safety technologies in secure federal settings.

“This agreement represents a transformational step forward in our federal strategy,” said William Santana Li, Chairman and CEO, Knightscope. “By joining Palantir’s FedStart program, we are preparing to deliver our autonomous security technology into some of the most mission-critical and security-conscious environments in the Nation. This collaboration aligns strongly with current momentum in Washington toward establishing a National Robotics Strategy to ensure U.S. leadership in autonomous systems.”

Under the agreement, Knightscope will operate its software within Palantir-managed AWS GovCloud clusters, ensuring compliance through accredited infrastructure, continuous monitoring, and quarterly third-party assessments – all critical to achieving and maintaining federal ATO status.

The partnership comes amid growing calls for a National Robotics Strategy aimed at strengthening domestic innovation, countering foreign influence in robotics, and modernizing U.S. government operations. Through FedStart, Knightscope is positioned to scale its solutions in service of national security, public safety, and critical infrastructure protection.

Palantir’s stated mission to empower American institutions with secure, AI-driven platforms reinforces alignment between the two companies. In a 2024 shareholder letter, Palantir CEO Alex Karp emphasized the company’s role in deploying operational AI “to protect liberty and support public institutions” – a vision that echoes Knightscope’s public safety mission.

“As federal leaders look to autonomous technologies to enhance operations and resilience, Knightscope is investing in the infrastructure, partnerships, and accreditations that will enable us to lead,” added Li.

Management

William Santana Li – Chairman And CEO

At 28, William Santana Li became the youngest senior executive at Ford Motor Company worldwide. With more than 30 years of experience, he has led multiple startups and held key roles across the global automotive industry, including Director of Mergers and Acquisitions at Ford. He later raised $250 million to co-found and serve as COO of GreenLeaf LLC, a Ford subsidiary, and went on to launch Carbon Motors Corporation, creator of the first purpose-built law enforcement patrol vehicle.

Mercedes Soria – EVP And Chief Intelligence Officer / CISO

With over 15 years of experience in systems development and software architecture, Soria is a technology professional who previously led IT strategy at Carbon Motors Corporation and is former Deloitte. Her expertise drives Knightscope’s intelligence and technological advancements.

Apoorv S Dwivedi – EVP And Chief Financial Officer

Dwivedi brings extensive finance and corporate strategy experience. He served as CFO of Nxu, Inc. (NXU), leading it to a successful Nasdaq listing. His background includes key roles at Cox Automotive, Workiva, and General Electric, where he honed his skills in finance operations and corporate growth.

Aaron J Lehnhardt – EVP And Chief Design Officer

Lehnhardt, Knightscope’s Chief Design Officer since 2015, previously led design at California Motors and co-owned Lehnhardt Creative LLC. His work spans advanced vehicle design, military projects, and innovative personal mobility solutions.

‍

NEWS

Sep 8, 2025

Knightscope Signs Another $1M in Renewals, Expansions and New Sales Won

Sep 4, 2025

Knightscope Reports Second Quarter 2025 Financial Results

Aug 13, 2025

Knightscope Closes Another $1.3M in New Sales Wins, Renewals & Expansions

Jul 23, 2025

Knightscope Joins Forces with Palantir to Advance Public Safety

Jul 17, 2025

Knightscope Secures Another $1M in New Sales, Renewals & Expansions; Gains Momentum on Capitol Hill

Jul 2, 2025

Knightscope Exceeds $1M in Contracts in New Sales & Renewals

Jun 2, 2025

Knightscope Reports First Quarter 2025 Financial Results

May 14, 2025

Knightscope Joins AUVSI to Advance Autonomous Systems Policy

May 9, 2025

Knightscope Secures $1.2+ Million Boost in Sales Won and Client Base Growth

Apr 24, 2025

Knightscope Secures New 33,000 Sq Ft Silicon Valley Headquarters to Power Next Phase of Growth as a New Era Begins

Apr 10, 2025

Knightscope Surges with $2+ Million in Sales, Renewals and Expansions

Apr 3, 2025

Knightscope Reports FY 2024 Results

Mar 31, 2025

Knightscope Closes $1.7 Million Registered Direct Offering of Common Stock

Mar 31, 2025

Knightscope Announces $1.7 Million Registered Direct Offering of Common Stock

Mar 28, 2025

Knightscope and Alliance Entertainment Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Mar 21, 2025

Knightscope Submits AI Recommendations to White House

Mar 18, 2025

On the Move: 107 Knightscope Machines & Devices

Mar 10, 2025

Knightscope Gains Momentum: Sales, Expansion and Upgrades Continue

Feb 20, 2025

SINCERELY,

DISCLAIMER

THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.

OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF TWENTY THOUSAND USD BY LFG EQUITIES CORP FOR A ONE DAY KSCP AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.

***Sponsored by LFG Equities Corp and Disseminated on Behalf of STREAMEX Corp

Streamex Exchange Corp NASDAQ-STEX Creates a Tokenized Yield-Bearing Gold Product Generating up-to 4% through Exclusive Partnership with Monetary Metals

STEX & Simplify Asset Management $10 billion USD AUM ETF Manager Announces Letter of Intent Pursuing a Strategic Partnership to Drive ETF Innovation through Integration of Tokenized Gold Yield Assets and Tokenization of Existing ETFs 

Tokenization goes Mainstream as the Nasdaq is working with U.S. regulators to introduce trading of tokenized securities!

__________________________________

Hello Everyone,

We have something New for you to take a look at for Thursday’s session. 

Pull up STEX right away. STEX has an institutional grade infrastructure to bring the gold and commodities market on chain. Enabled by a gold denominated treasury and tokenization technology powering the modern commodities market. 

Real World Asset (RWA) tokenization is the process of taking a tangible or traditional financial asset—like real estate, commodities, bonds, art, or private equity—and representing ownership of it on a blockchain as digital tokens. Instead of owning the physical asset directly, investors hold tokens that represent fractional ownership, rights, or claims to the asset.Then the tokens are recorded on a blockchain, making them easier to transfer, trade, and verify.

Streamex is led by a group of highly successful and seasoned executives from financial, commodities and blockchain industries.

STEX believes the future of finance lies in tokenization, innovative investment strategies, and decentralized markets. By merging advanced financial technologies with blockchain transparency, STEX has created infrastructure and solutions that enhance liquidity, accessibility, and efficiency. Streamex’s goal is to bridge the gap between traditional finance and the digital economy, unlocking new opportunities for investors and institutions worldwide.

There is no doubt that we are seeing Tokenization go mainstream!! The Nasdaq is currently working with U.S. regulators to introduce trading of tokenized securities, becoming the latest major financial player on Wall Street to double down on a boom in tokenization amid an easing of crypto regulations under the Trump administration.The same rails used for crypto and stablecoins are now powering real-world assets with full regulatory visibility. Liquidity is about to be redefined. When assets like gold, equity, or real estate become programmable and tradable 24/7, the financial system itself changes. Trust is being rebuilt digitally. On-chain assets offer provenance, transparency, and real-time auditability, the opposite of opacity and settlement delays in legacy systems.

Nasdaq isn’t the only company hopping on the trend. LSEG – The London Stock Exchange Group unveiled a Digital Markets Infrastructure (DMI) platform for private funds, supporting issuance, tokenization, and settlement in more digital form. WisdomTree launched a tokenized alternative income / private credit digital fund. These are just a few small examples. 

If you are not familiar with the technology then I suggest you acquaint yourself quickly. Some of biggest news announcements of 2025 have involved either tokenezations of assets or building crypto treasuries. Wall Street is falling in love with digital assets. 

STEX has dropped some BIG news announcements recently:

Streamex Exchange Corp NASDAQ-STEX Creates a Tokenized Yield-Bearing Gold Product Generating up-to 4% through Exclusive Partnership with Monetary Metals

Partnership unlocks exclusive tokenization rights, a four percent (4%) annual yield target on physical bullion, revenue share tied to leasing volumes and the creation of a groundbreaking institutionalized asset providing yield on physical gold holdings

Key Partnership Highlights

• Streamex secures exclusive tokenization rights for yield-bearing gold products through Monetary Metals
• Investors gain access to an estimated four percent (4%) annual yield through tokenized bullion assets and gold treasury
• Strategic structure includes revenue share tied to gold leasing volumes on Monetary Metals’ platform

LOS ANGELES and SCOTTSDALE, Ariz., Sept. 08, 2025 (GLOBE NEWSWIRE) — BioSig Technologies, Inc., which recently merged with Streamex Exchange Corporation (“Streamex”) (Nasdaq: STEX), together with Monetary Metals, a pioneer in gold and silver denominated financial products and strategies, today announced an exclusive long-term strategic partnership to launch a groundbreaking up to 4% yield generating gold product supported by Streamex’s tokenization and treasury platforms.

Through this collaboration, Streamex will gain exclusive rights to tokenize yield-bearing gold products while Monetary Metals provides access to its precious metals leasing and bond programs. Through the partnership, Streamex expects to offer investors an opportunity to earn an estimated four percent (4%) return on the tokenized gold bullion products that the Company will offer, as well as earning a return on the Company’s own gold treasury holdings.

“This collaboration represents a breakthrough in bridging the traditional gold market with digital assets,” said Henry McPhie, CEO of BioSig and Co-Founder of Streamex. “By earning yield on our gold holdings and creating tokenized yield products, we are building the foundation for scalable, institutional-grade instruments that can support billions of dollars in investment and unlock entirely new opportunities for investors.”

Under the agreement, Streamex will act as the exclusive tokenization partner of Monetary Metals for a minimum of three years, creating and distributing yield-bearing digital assets that combine the strength of physical bullion with the innovation of blockchain-based markets. Streamex will fund at least ten percent of the book of eligible Monetary Metals’ gold leases.

The agreement also provides Streamex with a revenue share tied to leasing volumes on Monetary Metals’ platform. This structure creates a mutually aligned model designed to scale significantly, institutionalizing yield-bearing bullion products backed by a comprehensive treasury strategy.

“Gold is a global, financial asset with deep liquidity. Paying fees to let it sit idle in a vault should not be the only option. Our vision has been to unlock gold’s natural utility by using it to finance real-world businesses and generate a yield,” said Keith Weiner, Founder and CEO of Monetary Metals. “We are excited to work with Streamex to create new ways to deliver gold yield to global markets, including tokenized solutions that combine the trust of gold with the accessibility of blockchain. This partnership is a major step on the road to gold reclaiming its place in global finance.”

About Streamex

Streamex is an RWA tokenization company building Institutional grade infrastructure to bring the gold and commodities market on chain, enabled by a gold denominated treasury and tokenization technology powering the modern commodities market. Streamex is a wholly owned subsidiary of BioSig Technologies, Inc.

About Monetary Metals

Monetary Metals® is Unlocking the Productivity of Gold™ by offering a Yield on Gold, Paid in Gold® to investors, and Gold Financing, Simplified™ to gold-using businesses (mints, miners, refiners, jewelers, etc.). Since 2016, individuals and institutions around the world have been earning interest in gold and silver every month through its Gold Yield Marketplace®.

ADD

Streamex Corp., NASDAQ: STEX & Simplify Asset Management $10 billion USD AUM ETF Manager Announces Letter of Intent Pursuing a Strategic Partnership to Drive ETF Innovation through Integration of Tokenized Gold Yield Assets and Tokenization of Existing ETFs

Partnership with Simplify Asset Management Unlocks Significant Opportunity for Demand of Streamex’s Yield-Bearing Gold Token and additional tokenization opportunities with Simplify, AUM of $10,017,260,875 as of 09/15/2025

September 17, 2025 19:01 ET  | Source: Streamex Corp.

Key Partnership Highlights:

• Streamex & Simplify have entered into a letter of intent outlining a framework for pursuing a strategic partnership to leverage each other’s platforms for next-generation financial products.
• Focus on the integration of Streamex’s tokenized yield-bearing gold into ETF structures, bridging blockchain innovation with institutional-grade financial products.
• Distribution expansion across both partners’ platforms, subject to definitive agreements and regulatory approval.
• Jointly intending to collaborate, subject to definitive agreements, on developing ETP/ETF offerings designed to expand investor access to regulated, liquid, and yield-generating gold and commodity-backed products.

NEW YORK and LOS ANGELES, Sept. 17, 2025 (GLOBE NEWSWIRE) — Streamex Corp. (“Streamex”) (NASDAQ: STEX), a leader in institutional-grade tokenization of real-world assets, today announced the signing of a letter of intent with Simplify Asset Management (“Simplify”), an exchange-traded fund (“ETF”) manager with more than $10 billion USD in assets under management. The potential partnership intends to explore the integration of Streamex’s tokenized gold yield product within Simplify’s ETF structures and establish a framework to co-develop tokenized exchange-traded product (“ETP”)/ETF solutions, subject to definitive agreements and regulatory approval.

Under the terms of the letter of intent, Streamex and Simplify intend to collaborate to design, launch, and distribute products that integrate tokenized commodities, beginning with gold, into ETF and ETP vehicles. This effort aims to expand ETF innovation beyond traditional equities and fixed income, while providing scalable, blockchain-enabled access to yield-bearing precious metal strategies.

Through this potential partnership, Streamex’s yield-bearing gold token may be embedded directly into Simplify’s ETFs, effectively bridging blockchain-based tokenization with the regulated ETF market. This integration is expected to create significant institutional demand for Streamex’s Gold Yield Token by providing ETF investors with direct exposure to yield-generating, tokenized gold assets within trusted, liquid, and regulated products.

“This is a transformative step in uniting the $10 trillion USD ETF industry with the innovation of real-world asset tokenization,” said Henry McPhie, CEO of Streamex Corp. “Simplify’s reputation for product innovation and deep ETF distribution, combined with Streamex’s tokenized gold infrastructure, will unlock new pathways for institutional and retail investors to access yield on gold inside regulated ETF wrappers.”

“Gold is a cornerstone of global portfolios, but until now, investors have been limited to non-yielding exposures,” said Paul Kim, CEO & Co-Founder of Simplify Asset Management. “By incorporating Streamex’s tokenized gold yield products into our ETFs, we are unlocking an entirely new investment category: regulated, yield-bearing gold accessible through the familiar ETF structure.”

STEX Engages CXG to Acquire FINRA/SEC-Registered Broker-Dealer to Expand Publicly Traded RWA Tokenization Operations

Will Position Streamex as one of the first NASDAQ Listed SEC and FINRA Compliant Issuers of RWA Tokens in the U.S.

LOS ANGELES & VANCOUVER, British Columbia–(BUSINESS WIRE)– BioSig Technologies, Inc. (NASDAQ: STEX) (“BioSig”), which recently merged with Streamex Exchange Corporation (“Streamex”) (together, “STEX” or the “Company”), is excited to announce a critical step toward becoming one of the first fully regulated Real-World Asset (“RWA”) tokenization companies trading on a major United States exchange: Streamex has engaged Compliance Exchange Group (CXG) to lead and manage the acquisition of a specific FINRA and SEC registered broker-dealer with licensed operations.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250714401245/en/

• Acquisition of the broker dealer, once complete, will create an entity with a significant first-mover advantage in U.S.-major-exchange-traded RWA-backed tokenized investment opportunities for both major institutional and retail investors in the U.S.
• This capability is expected to significantly accelerate adoption and network effect growth of Streamex’s proprietary on-chain RWA commodity market platform.
• The Company will also continue to seek out other broker-dealer opportunities in other strategically advantageous countries.

Management notes the near-term vision is to provide access to fully compliant, gold-backed tokenized assets for U.S. institutional and retail investors targeting the $22 trillion global gold market within the $142 trillion commodities sector, while engaging network-effect-based accelerating growth for the Streamex proprietary on-chain RWA-backed commodity exchange and financing ecosystem.

Strategic Benefits After Acquisition

• First-Mover Advantage: Streamex will be among the first Nasdaq-listed companies to issue regulated, gold-backed RWA tokens.
• Regulatory Compliance: Full compliance with both FINRA and SEC regulations, aligning with emerging U.S. digital asset frameworks.
• Scalable Platform: Streamex’s Solana-based blockchain enables fast, low-cost issuance and trading of gold-backed tokens, making gold investment accessible to all, with additional commodities markets to come.
• Gold-Backed Growth: Streamex aims to hold significant quantities in vaulted gold by 2026, denominating its balance sheet in physical gold to support a recurring revenue model.

Why It Matters

Near term, the acquisition positions Streamex to bridge traditional finance and blockchain, offering a seamless way to invest in physical gold through digital tokens. Investors can buy fractional shares of gold with the ease of cryptocurrency, while businesses gain new ways to raise capital. This move aligns with global trends, as institutions like BlackRock and Goldman Sachs tokenize billions in assets, and U.S. regulators begin to clarify digital asset rules.

“The acquisition will be a defining moment for Streamex and BioSig,” said Henry McPhie, CEO of BioSig and Co-Founder of Streamex. “Acquiring a regulated broker-dealer will help us build the infrastructure to lead the gold tokenization market in the U.S. Our Nasdaq listing and gold-backed platform will unlock unprecedented opportunities for investors and reshape the $22trillion gold market.”

Morgan Lekstrom, Executive Chairman of the Company, added: “Tokenizing gold is the future of commodity finance. Streamex’s regulated approach and public market presence make it a pioneer in this transformative space, with the potential to redefine how investors access real assets.”

About the Acquisition

The FINRA and SEC-registered broker-dealer, with a presence the U.S., will provide Streamex with the regulatory framework to issue and trade tokenized assets under federal securities laws. Compliance Exchange Group (CXG), a leader in broker-dealer compliance, will oversee the acquisition to ensure seamless integration and adherence to regulations. This acquisition is a critical step toward scaling Streamex’s RWA tokenization platform nationwide.

About Streamex Exchange Corporation

Streamex is a gold treasury and infrastructure company building the foundation for on-chain commodity markets. With a focus on real-world asset (RWA) tokenization, Streamex is developing a vertically integrated platform that combines token issuance, trading infrastructure, and physical gold holdings positioning the Company to become one of Nasdaq’s largest public holders of gold bullion.

This strategic approach aligns with Streamex’s mission to reshape global finance by bringing the approximately $142 trillion global commodities market on chain. By merging the security and trust of physical gold with the efficiency and transparency of blockchain, Streamex is creating scalable financial infrastructure for a new era of digital commodities.

The Company plans to hold significant quantities of physical gold, securely vaulted through a top-tier bullion bank. Streamex will denominate the majority of its balance sheet in vaulted gold rather than fiat currency, supporting a long-term, value-based financial model. Combined with Streamex’s Solana-based blockchain infrastructure, this strategy enables a recurring revenue model that supports the issuance of gold-backed digital assets.

Streamex is a wholly owned subsidiary of BioSig Technologies, Inc.

About Compliance Exchange Group (CXG)

CXG specializes in building, managing and supporting Broker-Dealer infrastructure, offering full-service compliance, registration, principal outsourcing, and advisory services.

NEWS

Streamex Corp., NASDAQ: STEX & Simplify Asset Management $10 billion USD AUM ETF Manager Announces Letter of Intent Pursuing a Strategic Partnership to Drive ETF Innovation through Integration of Tokenized Gold Yield Assets and Tokenization of Existin…

7 days ago

Streamex Corp., NASDAQ: STEX & Simplify Asset Management $10 billion USD AUM ETF Manager Announces Letter of Intent Pursuing a Strategic Partnership to Drive ETF Innovation through Integration of Tokenized Gold Yield Assets and Tokenization of Existin…

Sep 17, 2025

BioSig Technologies, Inc. Announces Corporate Rebrand to Streamex Corp.

Sep 10, 2025

Monetary Metals Enters into Exclusive Partnership with Streamex (Nasdaq: STEX) to Create Tokenized Yield-Bearing Gold Products

Sep 9, 2025

Streamex Exchange Corp NASDAQ-STEX Creates a Tokenized Yield-Bearing Gold Product Generating up-to 4% through Exclusive Partnership with Monetary Metals

Sep 8, 2025

BioSig Technologies Supplements Clarification on Recent Schedule 14A Filing. Closing of Merger with Streamex Exchange Corporation Not Affected

Sep 2, 2025

Streamex (STEX) to Participate in the 5th Annual Needham Virtual Crypto 1×1 Conference on September 4th

Aug 28, 2025

BioSig Technologies, Inc. & Streamex Announce Closing of $15 Million Public Offering

Aug 15, 2025

BioSig Technologies Inc. Announces Pricing of $15 Million Public Offering

Aug 13, 2025

‍

MANAGEMENT

SINCERELY,

DISCLAIMER

THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.

OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF TWENTY THOUSAND USD BY LFG EQUITIES CORP FOR A ONE DAY STEX AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.

***Sponsored by LFG Equities Corp.

Clinical evaluation of GEO-MVA, vaccine candidate for protection against Mpox and Smallpox, expected to initiate in second half of 2025

GeoVax Receives Favorable European Regulatory Guidance Supporting Streamlined Development Pathway for GEO-MVA

GeoVax to Advance Gedeptin(R) Into First-Line Therapy Neoadjuvant Combination Trial Following Landmark KEYNOTE-689 Results

‍

READ THE INVESTOR PRESENTATION HERE

_________________________

Hello Everyone,

We are coming off of another busy week. The markets are hitting all time highs and traders are hungry right now. There are a lot of opportunities right now to take into consideration. Our recent gold alert that we have been covering since $6 and more recently $14 just hit an all time high of $16.57 during Monday’s session.

That is not the only one that has taken off in the past few weeks. There are several examples.

Moving on we want you to turn your attention to GOVX immediately ahead of Tuesday’s session.

GeoVax is looking forward to presenting CM04S1 clinical progress at the Emerging Growth Conference.

The event will provide investors and stakeholders an opportunity to hear directly from CEO, David Dodd.

Read the release: https://t.co/9LSuXOLmmG $GOVX #Biotech #BusinessUpdate pic.twitter.com/DurU9BqQU8

— GeoVax, Inc. (@Geovax_News) September 18, 2025

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines for many of the world’s most threatening infectious diseases and therapies for

solid tumor cancers. The company’s lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine for which GeoVax was recently awarded a BARDA-funded contract to sponsor a 10,000-participant Phase 2b clinical trial to evaluate the efficacy of GEO-CM04S1 versus an approved COVID-19 vaccine. In addition, GEO-CM04S1 is currently in three Phase 2 clinical trials, being evaluated as (1) a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, (2) a booster vaccine in patients with chronic lymphocytic leukemia (CLL) and (3) a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin®, having recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. A Phase 2 clinical trial in first recurrent head and neck cancer, evaluating Gedeptin® combined with an immune checkpoint inhibitor is planned to initiate during the first half of 2025. GeoVax has a strong IP portfolio in support of its technologies and product candidates, holding worldwide rights for its technologies and products. The Company has a leadership team who have driven significant value creation across multiple life science companies over the past several decades.

The market is massive and the prospects are enormous.

Recently, Bavarian Nordic, a European vaccine maker of Mpox and Small Pox vaccines was offered $3B in a private equity buyout offer, which looks to be moving forward. In 2024, their MVA vaccine program generated $462M in revenue. This is not suggesting GeoVax will get a $3B buyout also, but is definitely indicative of the large potential of the market GeoVax is addressing and the strong interest from large industry players/investors.

https://www.reuters.com/business/healthcare-pharmaceuticals/nordic-capital-permira-make-3-billion-offer-vaccine-maker-bavarian-nordic-2025-07-28

GeoVax’s GEO-MVA candidate leverages a proprietary MVA vector to address the Mpox crisis and the ongoing threat of smallpox, offering broad protection, scalability, and resilience in vaccine supply. Unlike Bavarian Nordic, GeoVax is based in the U.S. and has invested heavily in a continuous cell line manufacturing process that supports large-scale, rapid, and cost-efficient production—an upgrade over traditional egg-based methods. This positions GeoVax to supply not only domestic needs but also bolster global pandemic preparedness and biosecurity, as recognized by recent favorable regulatory guidance from the European Medicines Agency (EMA) permitting a fast-tracked pathway to approval.

Another catalyst to take into consideration is an event taking place later in the week where GOVX will be presenting. A lot of eyes will be on the company this week and as we just implied, this is a highly active sector after the recent pandemic.

GeoVax to Present CM04S1 Clinical Progress at the Emerging Growth Conference

Next-Generation Multi-Antigen COVID-19 Vaccine Demonstrates Differentiated Immune Responses in Immunocompromised Patients

ATLANTA, GA – September 18, 2025 (NEWMEDIAWIRE) – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies for infectious diseases and cancer, today announced that it will present at the Emerging Growth Conference on Thursday, September 25, 2025. This live, interactive online event will provide investors and stakeholders an opportunity to hear directly from the Company’s Chairman and CEO, David Dodd, and participate in a real-time Q&A session.

Mr. Dodd will highlight recent positive interim clinical results for GEO-CM04S1, GeoVax’s lead COVID-19 vaccine candidate, which were presented this month at two major international scientific meetings:

• International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2025 (Krakow, Poland): Phase 2 data in chronic lymphocytic leukemia (CLL) patients showed that CM04S1 achieved the study’s immune response primary endpoint, while the comparator mRNA vaccine did not. Based on the Data Safety Monitoring Board recommendation, further enrollment is proceeding exclusively in the CM04S1 arm.
• European Society of Clinical Microbiology and Infectious Disease (ESCMID) 2025 (Lisbon, Portugal): Interim results demonstrated robust, durable T-cell and cross-variant antibody responses in immunocompromised blood cancer and post-transplant patients, with no serious adverse events reported. The data reinforce CM04S1’s differentiation versus standard-of-care vaccines.

“These results underscore the promise of CM04S1 as a multi-antigen solution for patients left behind by first-generation COVID-19 vaccines,” said David Dodd, Chairman & CEO of GeoVax. “Our MVA platform is demonstrating the potential to deliver broad, durable immune protection where it is needed most.”

Conference Participation

Mr. Dodd will present from 3:55 PM to 4:05 PM Eastern Time. Register here to attend the conference and receive event updates: https://goto.webcasts.com/starthere.jsp?ei=1717091&tp_key=c78a55764a&sti=govx

Participants may submit questions in advance to Questions@EmergingGrowth.com or ask them live during the presentation. A replay will be made available following the event on www.EmergingGrowth.com and the Emerging Growth YouTube channel: YouTube.com/EmergingGrowthConference.

GeoVax Showcases Positive Phase 2 Data for GEO-CM04S1 in CLL Patients at the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Conference

Multi-Antigen COVID-19 Vaccine Candidate Outperforms mRNA Comparator; Enrollment Now Limited to GEO-CM04S1 Arm

ATLANTA, GA – September 15, 2025 (NEWMEDIAWIRE) – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies for infectious diseases and cancer, today showcased positive interim results for its lead COVID-19 vaccine candidate, GEO-CM04S1 at the XXI International Workshop on Chronic Lymphocytic Leukemia (iwCLL 2025) in Krakow, Poland.

The presentation by Alexey V. Danilov, MD, PhD, Professor, Department of Hematology and Transplantation at City of Hope, detailed data from an ongoing randomized Phase 2 trial (NCT05672355) comparing GEO-CM04S1 to a standard-of-care mRNA vaccine in patients with chronic lymphocytic leukemia (CLL).

Key Takeaways

• Differentiated Performance: The proportion of CLL patients receiving GEO-CM04S1 that achieved the study’s primary immune endpoint met the statistical requirement to continue enrollment, while those in the mRNA COVID-19 vaccine arm did not.
• Enrollment Shifted to GEO-CM04S1: Following interim analysis and following the recommendation of the Data Safety Monitoring Board, further enrollment is proceeding exclusively in the GEO-CM04S1 arm.
• Durable Market Potential: CLL patients represent a high-need, underserved market where first-generation COVID-19 vaccines are often inadequate.
• Favorable Safety Profile: Both vaccines were well tolerated, with no grade greater than or equal to 3 adverse events reported.

“These data reinforce the value proposition of our multi-antigen MVA platform,” said David Dodd, Chairman & CEO of GeoVax. “Immunocompromised patients, including those with CLL, have not been adequately protected by current vaccines. GEO-CM04S1 is demonstrating the ability to overcome this gap, representing not only a clinical breakthrough but also a compelling commercial opportunity.”

About GEO-CM04S1

GEO-CM04S1 is a next-generation COVID-19 vaccine built on a Modified Vaccinia Ankara (MVA) vector. Unlike first-generation vaccines, GEO-CM04S1 encodes both the Spike (S) and Nucleocapsid (N) proteins of SARS-CoV-2 to drive broad, cross-variant, and durable immune protection. The vaccine is currently in three Phase 2 clinical trials:

1. As a primary vaccine for immunocompromised patients with blood cancers or post-transplant status,
2. As a booster in CLL patients, and
3. As a more robust COVID-19 booster in previously mRNA-vaccinated healthy adults.

Strategic Opportunity

With millions of immunocompromised patients worldwide, including those with CLL and other hematologic malignancies, GEO-CM04S1 addresses a significant unmet medical and commercial need. The vaccine’s ability to induce nucleocapsid-specific responses sets it apart from existing single-antigen mRNA products, positioning GeoVax to lead in a multi-billion-dollar market segment where durable protection remains elusive.

MVA TECHNOLOGY OVERVIEW

GeoVax’s vaccines are constructed to induce broader immunity through inclusion of multiple antigens into a single virus/vaccine platform. This is possible through the use of the company’s MVA vaccine platform, a large virus capable of incorporating multiple antigens into a vaccine platform.

Utilizing MVA, as a vaccine vector, allows for the targeting of multiple sites on a pathogen or cancer cell. Doing this is intended to result in a more robust and durable protective immune response. In addition, using MVA as a vaccine platform allows for the construction of vaccines which are capable of generating virus-like particles (VLPs) in the person receiving the vaccine.

The production of VLPs in the person being vaccinated is intended to mimic viral production that occurs in a natural infection, stimulating both the humoral (antibody) and cellular (T-cell) arms of the immune system to recognize, prevent, and control future infections.

MVA vectored vaccines can elicit durable (long-acting) immune responses while also possessing an excellent safety profile. MVA-VLP vaccines are designed to mimic authentic viruses in form but are not infectious or capable of replicating. As a result, VLPs can cause the body’s immune system to recognize and kill targeted infectious agents to prevent an infection or can be designed to target cancerous cells resulting in inhibited growth or destruction of tumors. VLPs can also train the immune system to recognize and kill virus-infected cells to control infection and reduce the length and severity of disease.

GEDEPTIN TECHNOLOGY OVERVIEW

A Phase 1/2 trial (NCT03754933), evaluating the safety and efficacy of repeat cycles of Gedeptin therapy in patients with recurrent head and neck squamous cell carcinoma (HNSCC), with tumor(s) accessible for injection and no curable treatment options recently completed enrollment at the Stanford University Cancer Institute, the Emory University Winship Cancer Institute, and the Thomas Jefferson University Sidney Kimmel Cancer Center.

The trial design involved repeat administration using Gedeptin followed by systemic fludarabine (prodrug). Expansion towards a larger, Phase 2 patient trial is anticipated. The FDA has granted Gedeptin orphan drug status for the intra-tumoral treatment of anatomically accessible oral and pharyngeal cancers, including cancers of the lip, tongue, gum, floor of mouth, salivary gland and other oral cavities. Also, the initial Phase 1/2 clinical study was funded by the FDA pursuant to its Orphan Products Clinical Trials Grants Program.

GeoVax to Advance Gedeptin(R) Into First-Line Therapy Neoadjuvant Combination Trial Following Landmark KEYNOTE-689 Results

Revised Phase 2 Strategy Targets Event-Free Survival in Primary Head and Neck Cancer through Checkpoint Inhibitor Combination

ATLANTA, GA – July 24, 2025 (NEWMEDIAWIRE) – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced a strategic shift in its Gedeptin® clinical development program, with a new emphasis on evaluating Gedeptin as a neoadjuvant therapy in combination with pembrolizumab for patients with primary, resectable head and neck squamous cell carcinoma (HNSCC).

The revised strategy follows the landmark results of the KEYNOTE-689 Phase 3 trial, published in the New England Journal of Medicine on June 18, 2025, which demonstrated a significant improvement in event-free survival (EFS) with the addition of perioperative pembrolizumab in resectable, locally advanced HNSCC patients. These data represent the first validated use of PD-1 inhibition in curative-intent HNSCC and have catalyzed a major shift in treatment paradigms toward neoadjuvant immunotherapy.

GeoVax’s new Phase 2 trial (AdPNP-203) will evaluate the addition of intra-tumoral Gedeptin®, intravenous fludarabine, and pembrolizumab in patients eligible for curative surgery. The trial is designed to assess major pathological response (MPR) and associated immunologic and biomarker outcomes following two pre-surgical cycles of therapy as well as event-free survival over a one-year period. Gedeptin’s tumor-targeting, immune-sensitizing mechanism may help overcome the limitations of checkpoint monotherapy by enhancing immune activation within the tumor microenvironment. Trial initiation is planned for 2026.

“The KEYNOTE-689 results support our view that neoadjuvant checkpoint inhibition can transform the treatment of head and neck cancer,” said Dr. Kelly McKee, Chief Medical Officer at GeoVax. “By integrating Gedeptin into this emerging standard, we hope to improve both local tumor clearance and event-free survival, especially for high-risk or PD-L1-low patients.”

“This is a strategic shift in our program,” added David Dodd, Chairman and CEO of GeoVax. “We believe Gedeptin’s localized cytotoxic mechanism, when combined with systemic checkpoint inhibition for first-line treatment, can meaningfully improve therapeutic outcomes in patients with resectable HNSCC.”

Rationale for Combination Strategy

As highlighted in the NEJM editorial, the benefit in KEYNOTE-689 may be driven primarily by the neoadjuvant component of immunotherapy. However, many patients still experience local or distant relapse, underscoring the need for intensified strategies in the perioperative window. Gedeptin, with its dual cytotoxic and immune-priming mechanism, may serve as an ideal partner to checkpoint inhibitors by converting “cold” tumors into “hot” immunogenic targets.

GeoVax Receives Favorable European Regulatory Guidance Supporting Streamlined Development Pathway for GEO-MVA

Confirms Single Phase 3 Immuno-Bridging Trial Sufficient to Evaluate Efficacy and to Support a Marketing Authorization Application (MAA) For Vaccination against Mpox and Smallpox

ATLANTA, GA – June 16, 2025 (NEWMEDIAWIRE) – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies against infectious diseases and cancer, today announced that it has received positive Scientific Advice (SA) from the European Medicines Agency (EMA) for GEO-MVA, a Modified Vaccinia Ankara (MVA)-based vaccine for the prevention of Mpox and smallpox. The SA supports the suitability of GeoVax’s clinical and nonclinical development strategy. This feedback from EMA provides clear regulatory alignment and enables an efficient pathway toward potential approval, eliminating multiple development steps commonly required for vaccines.

The EMA’s Committee for Medicinal Products for Human Use (CHMP) confirmed the adequacy of GeoVax’s proposed non-clinical immuno-bridging and toxicity studies to support progression to a Phase 3 study and MAA, assuming no unexpected findings occur.  They also confirmed Phase 1 and Phase 2 trials could be omitted and that a single, robustly designed Phase 3 immuno-bridging trial against the approved MVA vaccine (Imvanex), if successful, would be sufficient to support an MAA for GEO-MVA via the centralized procedure. The CHMP also agreed with the Company’s proposed immunogenicity endpoints in order to demonstrate non-inferiority. GeoVax believes this guidance represents a potentially significant acceleration in the regulatory approval timeline.

“This positive guidance from EMA represents a major milestone in the global advancement of GEO-MVA and opens a strategic path toward regulatory approval in Europe,” said David Dodd, Chairman and CEO of GeoVax. “At a time when the world is dependent on a single supplier for the MVA-based Mpox and smallpox vaccine, the approval of GEO-MVA would represent an additional, expanded source of vaccine and strengthen global health resilience.” Dodd continued, “The timing of this regulatory development is particularly critical. Just last week, the World Health Organization issued its fourth declaration of Mpox as a Public Health Emergency of International Concern (PHEIC), citing the ongoing spread of both Clade I and II Mpox viruses across 25 African countries as well as the continued risk of geographical expansion. The emergence of the highly virulent Clade 1 across Africa, Europe, Asia and the U.S. – along with wastewater detection in multiple U.S. states – highlights the urgent need to expand vaccine availability and accelerate new options like GEO-MVA. We believe our MVA platform offers a critical alternative to current vaccine solutions, especially when paired with our progressing next-generation MVA manufacturing capabilities. EMA’s clear and constructive guidance significantly streamlines the regulatory pathway for GEO-MVA, bringing us closer to potentially meeting urgent global and domestic needs for Mpox and smallpox preparedness.”

The EMA’s agreement with GeoVax’s proposed immune-bridging strategy to support an MAA filing comes as public health authorities face mounting pressure to diversify vaccine supply amid escalating Mpox transmission and strained global stockpiles.

Dodd emphasized, “GEO-MVA addresses both immediate and long-term needs. In the short-term, it expands vaccine availability using the current Chicken Embryo Fibroblast (CEF) production method. GeoVax plans to shift to its next-generation AGE1 manufacturing platform is anticipated to provide scalable, cost-effective production within the U.S. and self-sufficiency in regions such as Africa. The global need for additional Mpox vaccine manufacturers is critical and we are committed to working with global regulators to ensure access, transparency, and manufacturing resilience.”

‍

NEWS

GeoVax to Present CM04S1 Clinical Progress at the Emerging Growth Conference

3 days ago

GeoVax Showcases Positive Phase 2 Data for GEO-CM04S1 in CLL Patients at the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Conference

6 days ago

GeoVax Showcases Promising GEO-CM04S1 Clinical Data at the European Society of Clinical Microbiology and Infectious Disease (ESCMID) Conference

Sep 12, 2025

GeoVax to Present Multi-Antigen COVID-19 Vaccine Clinical Data at September International Scientific Conferences

Sep 8, 2025

GeoVax to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025

GeoVax Announces Allowance of Patent Protecting Multi-Antigen COVID-19 Vaccine Constructs

Aug 20, 2025

GeoVax to Present at the Emerging Growth Conference on August 20, 2025

Aug 18, 2025

GeoVax Comments on HHS mRNA Vaccine Rollback: Urges Full Embrace of MVA-Based Multi-Antigen Vaccine

Aug 7, 2025

GeoVax Urges Immediate Action on Pandemic Preparedness as Biodefense Gaps Expose Fragile Supply Chains

Jul 30, 2025

GeoVax Accelerates Development of GEO-MVA Vaccine Amid Expanding Global Mpox Crisis and Reaffirmed WHO Emergency Designation

Jul 29, 2025

GeoVax Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 28, 2025

GeoVax Announces Research Program to Evaluate Needle-Free, Self-Administered GEO-MVA Vaccine Using Vaxxas Microarray Patch Technology

Jul 28, 2025

GeoVax to Advance Gedeptin(R) Into First-Line Therapy Neoadjuvant Combination Trial Following Landmark KEYNOTE-689 Results

Jul 24, 2025

GeoVax to Report Second Quarter 2025 Financial Results and Provide Corporate Update on July 28, 2025

Jul 22, 2025

GeoVax Highlights EMA Regulatory Milestone as Catalyst for Near-Term Revenue from GEO-MVA Mpox Vaccine

Jul 21, 2025

GeoVax Highlights Growing Urgency for Diversified Mpox Vaccine Supply as Global Outbreaks Expand

Jul 16, 2025

GeoVax to Present at the Emerging Growth Conference on July 16, 2025

Jul 14, 2025

GeoVax Highlights Critical Role of Multi-Antigen COVID-19 Vaccines as Nimbus Variant Underscores Persistent and Evolving Public Health Threat

Jul 3, 2025

GeoVax Responds to Growing Mpox Threat With Expedited EU Pathway and Platform Aligned to U.S. Biodefense Objectives

Jul 2, 2025

GeoVax to Raise Approximately $6 Million of Gross Proceeds in Public Offering

Jul 1, 2025

MANAGEMENT

SINCERELY,

DISCLAIMER

THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.

OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF TWENTY THOUSAND USD BY LFG EQUITIES CORP FOR A ONE DAY GOVX AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.

***Sponsored by Beyond Media, LLC

BURU is in the process of acquiring a Defense & Security Hub, which which the company anticipates to contribute over $50M in revenues for 2025

NUBURU Poised to Finalize Strategic Acquisition and Prepare the Adoption of Advanced Technology, Artificial Intelligence & Robotics Initiatives as It Awaits Italian Government ‘Golden Power’ Approval

NUBURU Reveals TEKNE as Targeted Acquisition in the Advanced Defense Technologies

Read the Investor Presentation HERE

_________________________

Hello Everyone,

We want you to put BURU back on your radar. This one has amassed quite a following and is sitting under .15 right now. Since we last looked at this one they announced an update regarding their proposed acquisition.

Have a read:

NUBURU Provides Shareholder Update on Strategic Progress and Path to Controlling Interest in Tekne

CENTENNIAL, Colo.–(BUSINESS WIRE)– NUBURU, Inc. (NYSE American: BURU) (“NUBURU” or the “Company”), a global pioneer in high-performance blue laser technology, today issued a Letter to Shareholders providing an update on recent progress and outlining the next phase of its strategy to build a comprehensive Defense & Security Hub.

Dear Shareholders,

Over the past several weeks, NUBURU has made significant progress in advancing our “transformation agenda”. One of the most important next steps in that process is the establishment of a capital foundation to drive that transformation. Coming news from the Company will provide plenty of context for that remark.

Simply put, take it as an unambiguous sign that we are fully committed to delivering on the milestones we have communicated over the past 6 months.

The foundation of our Defense & Security Hub is taking shape. This includes not only our core laser technology but also the integration of Tekne’s advanced defense and control platform and innovative software solutions aimed at digitalizing the operational resilience capabilities of any mission critical business. Together, these elements are designed to create a powerful ecosystem capable of addressing emerging defense and security needs across multiple markets.

We are particularly excited about the newly formed 80/20 U.S. joint venture between NUBURU (via Nuburu Defense, LLC) and Tekne S.p.A. (“Tekne”). This venture provides us with a strong platform to serve both the Americas, APAC and NATO countries, leveraging Tekne’s $7.5 million in existing non-Italian orders and its expanding pipeline. As announced by Tekne on October 24, the strategic alliance with Flyer Defense will further enhance our U.S. JV’s ability to deliver high-mobility defense solutions, beginning with the Flyer 72-HD vehicle. We believe this combination of proven demand, pipeline strength, and strategic partnerships positions the joint venture for meaningful near-term impact.

Looking ahead, our financing strategy will continue to prioritize stability and alignment. We favor deliberate steps to expand our access to long-term, supportive capital. Our intent is to work with stable investors who share our vision and who are aligned with the interests of our loyal shareholder base. We will avoid financing structures that undermine shareholder value and instead focus on transactions that directly support the growth of our Defense & Security Hub and allow us to evaluate opportunistic acquisitions in blue-laser and defense technology.

In short, we are executing the plan we laid out and steadily building the foundation for sustained value creation. The months ahead will bring critical milestones, and we are confident that the trajectory we are on will strengthen NUBURU’s position as a leading player in defense technology innovation.

We will have more news over coming days that should add clarity and credibility to the path we have outlined toward the establishment of a state-of-the-art Defense & Security Hub. Until then, we thank you for your continued support and commitment as we move forward together.

Sincerely, Alessandro Zamboni Executive Chairman NUBURU, Inc.

‍

BURU is executing a bold transformation strategy in 2025, combining its core blue laser technology expertise with targeted expansion into defense, security, and operational resilience.

Through strategic acquisitions, leadership realignment, and international partnerships, the company aims to position itself as a leader in advanced industrial and defense solutions while navigating the inherent risks of such a significant corporate shift.

Founded in 2015, NUBURU is leading the transformation to a world of high-speed, high-quality metal machining and processing. In 2017, NUBURU changed the laser materials processing field with the introduction of the first industrial blue laser. Now at the forefront of this growth market, NUBURU’s groundbreaking blue laser technology has defined a new class of high-power, high-brightness blue lasers, starting with the standard AO® laser and the extreme-brightness AI™ laser, which enable radical gains in speed and quality for metal processing.

NUBURU’s blue laser is a leading solution for materials processing applications across e-mobility and automotive, energy storage, aerospace and additive manufacturing. In many industrial applications, critical materials such as copper, gold and aluminum do not absorb much of the infrared wavelengths transmitted by traditional industrial lasers, which leads to lower quality joints than by using NUBURU’s industrial blue lasers, which leverage a fundamental physical advantage to produce defect-free welds that are up to eight times faster than the traditional approaches — all with the flexibility inherent to laser processing. NUBURU’s blue lasers also address complex situations such as the joining of dissimilar metals.

BURU is intensifying its focus on defense and security applications, launching a strategic initiative to revitalize its laser business unit and develop new solutions tailored for the defense sector. BURU is in the process of acquiring a Defense & Security Hub, which is expected to contribute over $50Mn in revenue for 2025.

Strategic Corporate Update and Leadership Realignment

In April 2025, NUBURU announced a renewed focus on its blue-laser technology business. The company is collaborating with its previous management team to craft a new strategic plan aimed at reinvigorating its core technology and market approach. This move signals a commitment to leveraging its foundational expertise in blue laser solutions, renowned for enabling faster and higher-quality welds, particularly in the processing of copper, gold, and aluminum for advanced manufacturing applications.

Defense and Security Sector

A cornerstone of NUBURU’s new strategy is its aggressive push into the defense and security sectors. In early 2025, the company entered a strategic acquisition agreement with a private equity partner to create a dedicated hub for defense and security solutions.

This initiative involves:

• Recapitalization and integration of a specialized management team.
• Licensing of advanced technologies to enhance NUBURU’s defense offerings.
• Acquisition of a controlling stake in a defense technology firm focused on vehicles for industrial and military use, as well as electronic devices for advanced telecommunications and tracking.
• Investment in a software startup specializing in business continuity, ICT risk management, and cybersecurity—areas with strong synergy potential for the new hub.

NUBURU Reveals Its Strategic Trajectory in the Defense Sector

May 20, 2025 8:56am EDT

While NUBURU awaits the Italian government’s golden power, it outlines its defense go-to-market strategy and technological advancements

CENTENNIAL, Colo.–(BUSINESS WIRE)– NUBURU, Inc. (NYSE American: BURU), a leader in high-power blue laser technology, is proud to announce the official kick off of the working group made by the mutual management teams of BURU’ and the targeted defense-tech company (“DefenseTech Business”) part of the acquisition plan. The working group will also oversight the research and the development of advanced laser-tech-based solutions designed specifically for defense applications, as part of the Company’ strategic expansion in the defense sector, under the joint-pursuit agreement signed in March.

This announcement comes as NUBURU awaits approval from the Italian government under the “golden power” regulations, which oversee foreign investments in critical sectors aligned with national security interests.

As the Company continues to study the development and integration of its state-of-the-art laser technology with the expertise gained from its defense acquisition, the new comprehensive defense and security group strategy, to be delivered following the successfully completion of the acquisition plan, will comprise the enrichment of the portfolio of solutions with customized vehicles and advanced electronic products engineered for defense and civilian applications. The production of specialized vehicles – ranging from armored transport and emergency response vehicles to fuel tankers – leverages proprietary technology and components designed to meet the high-tech demands of modern defense requirements.

“Our strategic trajectory commits to providing advanced defense solutions is exemplified by our efforts to produce a diverse array of special-purpose vehicles, meticulously designed to support our military and civilian clients,” said Alessandro Zamboni, Executive Chairman of NUBURU. “Our plans aim at enhancing operational readiness and flexibility while ensuring our solutions are tailored for various mission profiles.”

Additionally, the defense-tech strategic plan targets to fortify the new enlarged group capabilities in electronic products for the defense and security sectors, offering a wide range of system solutions including jammers and telecommunication networks. Notably, the DefenseTech Business is currently actively developing innovative strategies to protect personnel and infrastructure through the deployment of cutting-edge jamming techniques.

Zamboni continues “In a significant development, our targeted DefenseTech Business has entered into a strategic partnership with a leading provider of tactical ground mobility solutions in the United States. Together, they will jointly produce a high-mobility vehicle designed for rapid deployment across a diverse landscape of military operations. Capable of reaching unprecedented levels of speed and range, this lightweight tactical vehicle excels in off-road conditions and is engineered for versatility in military missions. This collaboration will enhance the capabilities of the Italian Armed Forces and other NATO allies, fostering an environment of interoperability and readiness. The establishment of local production facilities in Italy will further streamline vehicle delivery and support, ensuring robust supply chain continuity and bolstering national defense initiatives.”

As previously disclosed, the targeted DefenseTech Business currently accounts a portfolio of approximately 60 clients across seven countries (including the USA, Italy, and UAE) and accounts a robust backlog of orders totaling $309 million, and options for an additional $181 million.

As NUBURU progresses, it emphasizes its dedication to leveraging advanced technologies and partnerships to lead within industries critical to national security and operational resilience.

NUBURU Reveals TEKNE as Targeted Acquisition in the Advanced Defense Technologies

May 22, 2025 8:35am EDT

The Acquisition, subject to regulatory and stockholders approval, will Enhance Revenue Streams to $50 Million as NUBURU Revitalizes Blue Laser Technology to be integrated within the new State-of-the Art Defense & Security Hub

CENTENNIAL, Colo.–(BUSINESS WIRE)– NUBURU, Inc. (NYSE American: BURU), a front-runner in high-power blue laser technology, reveals Tekne S.p.A. (“TEKNE”) as targeted acquisition, a distinguished provider of integrated electronic warfare and cyber capabilities within military vehicles.

As previously announced, NUBURU awaits approval from the Italian government under the “golden power” regulations, which oversee foreign investments in critical sectors aligned with national security interests. Also, the completion of the acquisition of TEKNE, part of the over-all plan to create a unique Defense & Security hub, is subject to the necessary regulatory and stockholders approval.

TEKNE, with an annual revenue of $50 million and a R&D team of 70 engineers and technicians, brings a wealth of expertise in telecommunications, electronic, and cyber warfare, along with state-of-the-art vehicle protection systems. As a pioneer in jammer technology, TEKNE has successfully supplied advanced systems up to 8GHz and is currently developing solutions for satellite systems, reinforcing its global presence among technologically advanced nations.

In addition to its innovative technology, TEKNE proudly serves a diverse client base, including key national organizations such ministers, government agencies and other public sector entities. This established global clientele highlights TEKNE’s credibility and the vital role it plays within the defense sector. Furthermore, TEKNE entered in 2024 into a strategic partnership with US Flyer Defense, a leading provider of tactical ground mobility solutions in the United States. Together, they are set to produce a high-mobility vehicle designed for rapid deployment across a diverse landscape of military operations. This lightweight tactical vehicle, engineered for versatility in military missions, will enhance the capabilities of the Italian Armed Forces and other NATO allies, fostering an environment of interoperability and readiness. On the other side, TEKNE already has commercial and support operations in the United States. The company plans to further expand its presence in the US market, including the establishment of a technology laboratory focused on serving the specific needs of American customers.

TEKNE’s portfolio also includes specialized vehicles designed for various applications, such as the Graelion 4×4 multi-purpose vehicle and the Shield armored vehicle tailored for personnel transport. Additionally, the company is recognized for its leadership in the field of Cyber Electromagnetic Activities (CEMA), a modern approach to electronic warfare that integrates cyber capabilities.

“Our targeted acquisition of TEKNE exemplifies our commitment to expanding within the vital defense sector while enhancing our capabilities to address complex security challenges,” said Alessandro Zamboni, Executive Chairman of NUBURU. “By integrating TEKNE’s advanced solutions with our blue laser innovations and niche-solutions in the operational resilience space, we are poised to deliver cutting-edge products that meet the ever-evolving needs within the $500 billion defense industry and the emerging regulatory requirements in the security market.”

By leveraging the existing TEKNE robust order backlog totaling $309 million and the potential synergies with “platform as a service” business models, NUBURU is well-positioned to ensure operational efficiencies and accelerate its growth in critical industries, creating value for its shareholders.

This announcement comes as NUBURU awaits approval from the Italian government under the “golden power” regulations, which oversee foreign in-vest-ments in critical sectors aligned with national security interests.

NEWS ‍

NUBURU Completes Public Offering and Raises $12M to Drive Strategic Growth in Defense Technology

21 hours ago

NUBURU Prices $12M Public Offering to Accelerate Strategic Transformation in DefenseTech Sector

2 days ago

NUBURU Provides Shareholder Update on Strategic Progress and Path to Controlling Interest in Tekne

Sep 9, 2025

NUBURU Hits First Milestone in Tekne Acquisition with Initial Stake and Tekne US JV Launch

Aug 21, 2025

NUBURU Charts Strategic Defense Trajectory Following Italian Government Guidance on TEKNE Acquisition

Aug 7, 2025

NUBURU Advances Toward Strategic Transformation as NYSE American Accepts Compliance Plan

Jul 24, 2025

NUBURU Stockholders Green-Light Strategy to Finance Transformation in Key Stockholder Vote

Jul 10, 2025

NUBURU Advances Defense-Tech Transformation with Strategic Acquisitions and €50M Military Deployment

Jun 27, 2025

NUBURU Accelerates M&A Strategy with $100 Million Flexible Growth Capital

Jun 2, 2025

NUBURU Reveals TEKNE as Targeted Acquisition in the Advanced Defense Technologies

May 22, 2025

NUBURU Reveals Its Strategic Trajectory in the Defense Sector

May 20, 2025

NUBURU Files $100M SEC Registration Statement to Enhance Capital Flexibility for Completion of Defense Acquisition and Blue Laser Technology Revitalization Targeting a $500B Defense Market

May 12, 2025

NUBURU Issues Notice and Plan for Resolution of Non-Compliance with NYSE Stockholders’ Equity Rule/Going Concern Qualification

May 5, 2025

NUBURU Unveils Strategic Initiative to Revitalize Blue-Laser Business Unit with New Applications in Defense Sector

May 5, 2025

NUBURU Secures Funding to Eliminate Outstanding Payables and Paves the Way for Strategic Acquisitions in Defense and Security Market

Apr 22, 2025

NUBURU Announces Strategic Corporate Update Focused on Defense & Security, Advanced Technologies, and Growth Initiatives

Apr 15, 2025

NUBURU, Inc. Announces Unwinding of Partnership with HUMBL, Inc.

Apr 10, 2025

NUBURU Advances Joint Development Agreement to Innovate Laser Applications in Defense Sector

Apr 1, 2025

NUBURU Announces Elimination of 100% of its Long-Term Indebtedness and $5.15 Million Strategic Investment in Supply@ME Capital

Mar 19, 2025

NUBURU Takes Strategic Leap Forward: First Acquisition Step in Defense and Security Sector Completed

Mar 12, 2025

COEPTIS’ NexGenAI Affiliates Partners with NUBURU Network to Drive Innovation in AI and Robotics as Part of its Transformation Plan

Mar 7, 2025

NUBURU Partners With COEPTIS NexGenAI Affiliates Network to Drive Innovation in AI and Robotics as Part of Its Transformation Plan

Mar 6, 2025

MANAGEMENT

SINCERELY,

DISCLAIMER

THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.

OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF TWENTY THOUSAND USD BY BEYOND MEDIA LLC FOR A ONE DAY BURU AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.

***Sponsored by Sideways Frequency, LLC

Atlas Lithium’s Neves Project Completes Definitive Feasibility Study Estimating 145% IRR and 11-Month Payback

Some of the company’s high-potential mineral rights are adjacent to or near large lithium deposits that belong to a large, publicly traded comparable that boasts a $1.2 Billion market cap!


Atlas Lithium secured a strategic partnership with Mitsui & Co., Ltd., one of Japan’s largest global trading and investment companies with operations in over 60 countries

Atlas Lithium Subsidiary’s Iron Quadrangle Project on Track for Q4 2025 Revenues

CHECK OUT THE INVESTOR PRESENTATION HERE ‍

$ATLX NEWS: Atlas Lithium's Critical Minerals Subsidiary Reports Strong Rare Earths, Titanium, And Graphite Results

Atlas Critical Minerals (OTCQB: JUPGF) reports high-grade, near-surface rare earths mineralization with grades up to 28,870 ppm TREO, 23.2% TiO₂; achieves 96.6%… pic.twitter.com/9Wzc7A4u2i

— Atlas Lithium (Nasdaq: ATLX) (@Atlas_Lithium) July 24, 2025

_________________________

Hello Everyone,

We want you to take another look at ATLX. You should be familiar with this one.

We looked at it over a month ago and it went from under 5 to 5.69

We just brought it to your attention back in July when it traded as low as 4.60. Just 7 sessions later it tapped 7 bucks on way above average interest.

It has pulled back under $5 while it has also amassed a big following in the past 6 months. We are seeing it average right around $2M in interest since the beginning of the Summer which is big after coming from humble beginnings.

We even just saw their partly owned subsidiary, Atlas Critical Minerals explode from under .75 to 2.65 in under 5 sessions last week.

Focused on moving from exploration to profitability; Atlas Lithium Corporation (NASDAQ: ATLX) is a U.S.-based mineral exploration company with the largest size and breadth of exploration projects for strategic minerals in Brazil, a premier mineral jurisdiction.

ATLX intends to be a leader in the provisioning of minerals essential to the transformation of the global economy from fossil fuels to electrification, a process which is expected to take decades.

The company’s properties encompass approximately 539 km2 for lithium, as well as mineral rights for nickel, rare earths, titanium and graphite. Atlas Lithium also owns 32% of Atlas Critical Minerals Corporation.

Over the last several years, Atlas Lithium has assembled Brazil’s largest portfolio of lithium mineral rights among publicly listed companies.

ATLX holds three key projects that span the major lithium-mineralized zones in LV:

1. The Neves Project in southern LV, Atlas Lithium’s flagship development, which has recently been permitted and is advancing towards production;

2. The Salinas Project in northern LV, spanning 2,070 acres with natural spodumene outcrops, and is located 4.7 miles from Latin Resources Ltd., and with potential for spodumene deposits;

3. The Clear Project in central LV, which encompasses 470 acres, is situated 3.8 miles from Sigma Lithium’s (NASDAQ: SGML) Grota do Cirilo mine. There is also potential for spodumene deposits. Sigma Lithium has a market cap of roughly $1.2B! (Note: ATLX’s lithium processing manager James Schloffer had a key role at Sigma!)

Atlas Lithium Subsidiary’s Iron Quadrangle Project on Track for Q4 2025 Revenues

Strategic Partnership Model Allows for Near-Term Cash Flow Generation

Boca Raton, Florida–(Newsfile Corp. – September 2, 2025) – Atlas Lithium Corporation (NASDAQ: ATLX) (“Atlas Lithium” or “Company”), a leading lithium development company advancing towards production at its flagship Neves Lithium Project, today announced significant progress by its 30%-owned subsidiary, Atlas Critical Minerals Corporation (OTCQB: JUPGF) (“Atlas Critical Minerals” or “ACM”). ACM’s Iron Quadrangle Project is expected to generate initial revenues in the fourth quarter of 2025 through a strategic partnership with an iron ore processing company, marking a major milestone in the Company’s diversified portfolio strategy.

The Iron Quadrangle Project, named after its world-renowned location in the State of Minas Gerais, Brazil, will leverage a capital-efficient revenue model through partnership with an established iron ore processor. Under this arrangement, mining operations and processing of extracted iron ore will be performed by the partner company, which owns processing facilities capable of transforming ACM’s unprocessed iron ore into high-quality sinter feed. Atlas Critical Minerals will receive revenues from its run-of-mine material and a percentage of the final sinter feed product sales. Figure 1 is a photograph of the plant expected to process ACM’s iron ore.

“This development represents a significant step forward for our portfolio of quality projects with reasonable timeline to production,” said Marc Fogassa, Chairman and CEO of Atlas Lithium Corporation. “Our ownership stake in Atlas Critical Minerals is expected to provide our shareholders with exposure to multiple minerals and their uncorrelated revenue streams. The Iron Quadrangle Project’s path to near-term profitability exemplifies this strategy.”

The Iron Quadrangle Project benefited from ACM’s systematic exploration and development. Atlas Critical Minerals acquired the mineral right in 2020, conducted detailed geological exploration including a drilling campaign covering approximately 10% of the area in 2021 and 2022, and published an initial technical report in accordance with U.S. guidelines in 2022. The Iron Quadrangle Project received a 10-year operational license from the State of Minas Gerais in May 2024 and its mineral right was granted mining concession status by the Ministry of Mines and Energy in May 2025.

Atlas Lithium’s Neves Project Completes Definitive Feasibility Study Estimating 145% IRR and 11-Month Payback

Boca Raton, Florida–(Newsfile Corp. – August 4, 2025) – Atlas Lithium Corporation (NASDAQ: ATLX) (“Atlas Lithium” or “Company”), a leading lithium development company, is pleased to announce that SGS Canada Inc. (“SGS”) has completed the Definitive Feasibility Study (“DFS”) for the Company’s 100%-owned Neves Lithium Project (“Project”), a technical report prepared under the U.S. guidelines of Item 1300 of Regulation S-K (“Regulation S-K 1300”). This hard-rock Project is well-suited to being a low-cost open-pit mining operation, as its spodumene deposits are located relatively close to the surface. Located in the state of Minas Gerais, Brazil, the Project encompasses 4 of the 98 mineral rights for lithium owned by Atlas Lithium. As detailed in the DFS, the Neves Project is expected to deliver strong financial metrics with an internal rate of return (“IRR”) of 145%, payback in 11 months from the start of operations, and an after-tax net present value (“NPV”) of $539 million. Importantly, the DFS estimates the Neves Project to have operational production costs of only $489 per tonne of lithium concentrate, positioning Atlas Lithium among the world’s lowest-cost producers. Complete details of these metrics can be found in the DFS, filed with the Securities and Exchange Commission as an exhibit to the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2025. Marc-Antoine Laporte from SGS serves as the Qualified Person for the DFS under Regulation S-K 1300. SGS is well-known as a global leader in testing, inspection, and certification services for mineral properties and projects.

Industry-Leading Capital Efficiency and Low Operating Costs

The DFS supports that expected direct capital expenditures of $57.6 million will be needed for the implementation of the Project, by far the lowest such capital costs among other announced projects in Brazil. Notably, Atlas Lithium has already invested approximately $30 million in acquiring and transporting the Project’s newly fabricated dense media separation (“DMS”) plant to Brazil, as previously reported. The Company has secured two non-dilutive pre-payment agreements for its lithium concentrate totaling $40 million and has received additional funding interest from other parties, including 10-year debt financing options, any of which could support the Project’s capital requirements.

The Company believes that the DFS validates the Project’s strong economics, positioning it among the most capital-efficient and lowest-cost hard-rock lithium developments globally. The Project will employ proven DMS technology, with comprehensive metallurgical testing demonstrating an expected robust lithium recovery rate of 61.7% to produce high-quality, low-impurity lithium concentrate. This relatively straightforward, low-risk DMS processing methodology minimizes technical complexity and operational risk while enabling a low environmental footprint.

Atlas Lithium’s mineral right to be mined, as detailed in the DFS, received its “Portaria de Lavra” (mining concession) status from Brazil’s Ministry of Mines and Energy on May 27, 2025 — the highest level of titleship in Brazil and one that allows continuous mining operations. Multiple deposit areas within the Project remain open for resource expansion along strike and at depth and are thus expected to extend the life of mine. Additionally, numerous high-potential geological targets remain within the Project’s mineral rights, providing compelling opportunities for future exploration.

Located in the established Araçuaí Pegmatite District in the Vale do Jequitinhonha, often called Lithium Valley, the Project benefits from favorable infrastructure, including proximity to transportation networks, water resources, and skilled labor. The Project qualifies for tax incentives from the Superintendency for the Development of the Northeast (SUDENE), as promulgated by Brazil’s Ministry of Integration and Regional Development, reducing the corporate tax rate from 34% to 15.25% and further enhancing profitability.

“The DFS indicates potentially outstanding returns for our initial vision of developing a focused, near-term, profitable lithium production asset with minimal capital requirements,” said Marc Fogassa, Chairman and CEO of Atlas Lithium. “The combination of our low capital intensity and rapid payback period is expected to create exceptional value for our shareholders while positioning Atlas Lithium to benefit from future organic expansion opportunities at Neves and other high-potential lithium areas that we own. Importantly, we are creating many quality employment opportunities in the Vale do Jequitinhonha region, representing a significant societal contribution of our Project.”

Experienced Leadership Driving Project Implementation

Following his leadership role in collaborating with SGS on the DFS, project implementation activities are being supervised by Eduardo Queiroz, Atlas Lithium’s Project Management Officer (PMO) and Vice President of Engineering. Mr. Queiroz has more than two decades of hands-on experience managing complex, large-scale mining projects.

“The DFS demonstrates the technical robustness of the Project, with proven DMS technology and comprehensive metallurgical test work validated by SGS, a premier firm in the lithium space,” said Mr. Queiroz. “With our processing plant fully fabricated and paid for, and now with the DFS in hand, we have systematically de-risked the Project. I am excited to lead the implementation phase of Atlas Lithium’s journey to becoming a lithium producer.”

Salinas and Clear: The Next Expansion Frontier

Atlas Lithium is strategically positioned to capitalize on its extensive regional lithium exploration portfolio in Brazil, particularly through advancement of its Salinas Project and Clear Project, both 100% owned by the Company. Atlas Lithium’s Salinas Project is just 5 miles east of the Colina lithium asset previously owned by Latin Resources — a major factor in Pilbara Minerals’s acquisition of that company in 2024 for approximately $370 million. At the Salinas Project, Atlas Lithium has already achieved promising initial results, including the discovery of spodumene-rich pegmatites very close to the surface, and highly positive results from soil geochemistry and from LIDAR geological mapping.

Atlas Lithium’s Clear Project is located less than 4 miles from Sigma Lithium’s operating lithium mine, and represents significant untapped potential with highly positive results from soil geochemistry and from LIDAR geological mapping.

Diversification in Critical Minerals

Atlas Lithium also owns approximately 30% of Atlas Critical Minerals Corporation (OTCQB: JUPGF), a separate company with exploration programs in uranium, rare earths, titanium, and graphite.

Atlas Lithium’s Critical Minerals Subsidiary Reports Strong Rare Earths, Titanium, and Graphite Results

Atlas Critical Minerals reports high-grade, near-surface rare earths mineralization with grades up to 28,870 ppm TREO, 23.2% TiO₂; achieves 96.6% graphite concentrate

Boca Raton, Florida–(Newsfile Corp. – July 24, 2025) – Atlas Lithium Corporation (NASDAQ: ATLX) (“Atlas Lithium” or the “Company”), a leading lithium exploration and development company, today announced strong results from its 30.1%-owned subsidiary, Atlas Critical Minerals Corporation (OTCQB: JUPGF). The subsidiary has recently reported near-surface rare earths mineralization with grades up to 28,870 ppm TREO, 23.2% TiO₂, alongside graphite concentrate results of up to 96.6%. Atlas Critical Minerals owns over 575,000+ acres of mineral rights for rare earths, titanium, graphite, uranium, copper, and nickel. Brazil, where the subsidiary operates, hosts significant rare earth deposits and holds the world’s second-largest graphite reserves.

Alto Paranaíba Rare Earths and Titanium Project Demonstrates High Potential

Atlas Critical Minerals’ Alto Paranaíba rare earths and titanium project in Minas Gerais, located in a proven rare earths region, is divided into three exploration blocks for operational efficiency as shown in Figure 1.

Figure 1: Alto Paranaíba Project Exploration Blocks

To view an enhanced version of this graphic, please visit: https://images.newsfilecorp.com/files/6706/259897_14822f5ff4efe99a_002full.jpg

Atlas Critical Minerals’ 770 surface samples yielded consistently attractive grades, including a sample with 28,870 ppm total rare earth oxides (TREO) and another containing 23.2% titanium dioxide (TiO₂). Highlight sampling results from Block 3 South are presented in Figure 2.

Figure 2: High-Grade Surface Sampling Results

To view an enhanced version of this graphic, please visit: https://images.newsfilecorp.com/files/6706/259897_14822f5ff4efe99a_003full.jpg

Graphite Project Delivers Outstanding Initial Results

Atlas Critical Minerals’ Minas Gerais graphite project achieved strong metallurgical test results, with conventional flotation techniques producing graphite concentrates grading up to 96.6% total graphite carbon. Exploration samples showed graphite carbon grades up to 15.42%.

Strategic Importance

The strategic importance of securing robust critical minerals supply chains was recently underscored by the U.S. Department of Defense’s $400 million investment in MP Materials, making it the largest shareholder in the U.S. rare earth miner.

Atlas Lithium’s strategic stake in Atlas Critical Minerals provides shareholders with direct exposure to the broader critical minerals sector and strengthens the Company’s position within global supply chains for materials vital to energy transition and national security.

“Our focus remains on advancing our flagship Neves lithium project toward production, while our significant stake in Atlas Critical Minerals allows our shareholders to also benefit from exposure to a broader range of critical minerals at a time of heightened geopolitical importance,” said Marc Fogassa, Chief Executive Officer and Chairman of Atlas Lithium. “The initial results from Atlas Critical Minerals’ rare earths, titanium, and graphite programs are highly encouraging and underscore the strong potential of these assets.”

Atlas Lithium’s Modular Processing Plant Arrives in Brazil, Achieving Critical Milestone Toward Production

‍

Boca Raton, Florida–(Newsfile Corp. – March 10, 2025) – Atlas Lithium Corporation(NASDAQ: ATLX), a leading lithium development company, announces the successful arrival of its modular Dense Media Separation (DMS) lithium processing plant at the Port of Santos, Brazil. This pivotal achievement underscores the Company’s progress toward becoming a key lithium producer in Brazil’s emerging Lithium Valley.

The components of Atlas Lithium’s lithium processing plant were carried by the cargo vessel Irene’s Wisdom (IMO: 9953391) which arrived at the Port of Santos on March 7, 2025, delivering 141 containers and 10 bulk components. Fully owned and paid for by Atlas Lithium, this newly manufactured facility departed from the Port of Durban, South Africa, on February 2, 2025, following months of careful planning and preparation. Two additional containers, containing spare parts, are scheduled to arrive in the near future.

“This marks a transformative milestone for Atlas Lithium as we advance toward becoming a global supplier in the lithium market,” said Marc Fogassa, Chairman and CEO of Atlas Lithium. “With operational permits secured and our modern lithium processing facility now in Brazil, we have overcome two of the most significant hurdles on our journey to production.”

Cutting-Edge Modular Plant Design

Atlas Lithium’s lithium processing plant incorporates advanced design elements and sustainable technology that set a new benchmark for lithium processing:

• Compact, Modular Design: Allows streamlined transportation, installation, and commissioning, reducing time to production.
• Reduced Environmental Footprint: Optimized physical layout minimizes environmental impact while maintaining high operational efficiency.
• Advanced Water Conservation: Internal recycling systems with lower water consumption compared to traditional plants.
• Sustainable Tailings Management: Dry-stacking technology eliminates the need for tailings dams, promoting greater environmental sustainability.

Strategic Progress Toward Production

The Neves Project, Atlas Lithium’s flagship operation, received its operational permit from the state of Minas Gerais in October 2024. The project is positioned to initially produce up to 150,000 tonnes per year of battery-grade spodumene concentrate, a critical raw material for lithium-ion batteries.

Atlas Lithium’s operations will benefit from Brazil’s Lithium Valley’s strategic advantages, including expected lower production costs as compared to suppliers from Australia and other regions.

Atlas Lithium Strengthens Position in Critical Minerals with Rare Earths, Titanium, Graphite, and Uranium Exposure

Boca Raton, Florida–(Newsfile Corp. – March 5, 2025) – Atlas Lithium Corporation(NASDAQ: ATLX), a leading lithium exploration and development company, is pleased to highlight its current 32.2% stake in Atlas Critical Minerals Corporation. This ownership positions Atlas Lithium at the forefront of Brazil’s critical minerals sector, providing exposure to rare earth elements, titanium, graphite, uranium, and other sought-after minerals.

“Global demand for critical minerals has never been more urgent,” said Marc Fogassa, CEO and Chairman of Atlas Lithium. “Recent geopolitical developments have underscored the vital importance of critical minerals for economic and national security. Atlas Lithium is strategically positioned to play a key role in this increasingly important sector.”

Rare Earths: Essential for Defense, Energy, and High-Tech Applications

Rare earth elements are indispensable components in manufacturing permanent magnets used in electric vehicle (EV) motors, wind turbines, and defense systems. With Chinacurrently controlling over 60% of global rare earth mining and 85% of refining capacity, recent export restrictions have underscored the need for alternative supply sources.

Atlas Critical Minerals’ extensive rare earth portfolio spans approximately 54,000 hectares (~133,000 acres) across 33 mineral rights in the states of Goiás and Minas Gerais in Brazil. These areas have demonstrated promising mineralization, with soil samples revealing rare earth oxide (TREO) concentrations as high as 15,000 ppm and titanium dioxide concentrations up to 20%.

Graphite: A Cornerstone of Battery Technology

Graphite is a critical component for lithium-ion batteries, which power electric vehicles and renewable energy storage systems. As global EV adoption accelerates, demand for natural graphite has surged, making the development of new sources outside of traditional suppliers like China a strategic imperative. Atlas Critical Minerals is actively evaluating areas in Brazil with known graphite formations, with the goal of contributing to the global supply of this essential material.

Uranium: Fueling the Energy Transition

Uranium is experiencing renewed global demand as nations prioritize energy security, geopolitical stability, and decarbonization. With nuclear power offering a reliable, low-carbon energy source, uranium has become integral to the energy transition. Atlas Critical Minerals is focused in certain areas in Brazil with promising geological characteristics for uranium. In Brazil, uranium is strictly regulated and exploration requires special permitting, which is not guaranteed. Nevertheless, this sector is expected to continue to grow substantially as Brazil activates its third nuclear reactor for electricity generation and as global demand continues to rise.

A Diversified Strategy for a Changing World

Atlas Lithium’s ownership stake in Atlas Critical Minerals strategically complements its flagship Neves Project in Brazil’s Lithium Valley. This diversified approach provides shareholders with exposure to multiple critical minerals essential for the global energy transition and advanced manufacturing sectors.

“In today’s environment of persistent geopolitical tensions, the need for reliable, diversified critical mineral supply chains has never been clearer,” added Fogassa. “While our immediate focus is to bring our lithium production online and generate profits, Atlas Lithium’s long-term strategy is to establish itself as a leader in the global critical minerals space.”

Strategic Partnership with Global Industrial Giant

In a transformative development, Atlas Lithium secured a strategic partnership with Mitsui & Co., Ltd., one of Japan’s largest global trading and investment companies with operations in over 60 countries. In March 2024, Mitsui demonstrated its confidence in Atlas Lithium’s potential by making a substantial US$30 million strategic investment at a 10% premium to market price. The partnership includes a significant offtake agreement lithium concentrate from Atlas Lithium’s Neves Project. Notably, Mitsui’s largest shareholder is Warren Buffett’s Berkshire Hathaway, adding another layer of institutional validation to Atlas Lithium’s business model.

‍

Within the global lithium industry, Brazil’s LV has emerged as a premier hard-rock lithium jurisdiction.

Brazil’s advantages include year-round mining operations, lower labor costs, and a supportive government. The country’s lithium industry outperforms Australian producers on costs; Pilbara Mineral’s US$370M acquisition of a Brazilian lithium explorer in August 2024 highlights the region’s importance.


“Investments in lithium production in Minas Gerais are projected to range from $3.9 billion to $5.8 billion by 2030,” according to João Paulo Braga, CEO of the state investment promotion agency, Invest Minas.

Few countries besides Brazil have such an advantageous position to attract investment, as other Latin American nations face uncertainties and political risks.

ATLX’s Minas Gerais Lithium Project is its largest endeavor and consists of 85 mineral rights totaling approximately 468 km2 which include seven main clusters of prospective mineralization: Neves (currently being explored by drilling campaign and referred to as the “Neves Project”), Coronel Murta, Eastern Properties, Itinga, Salinas, Santa Clara, and Tesouras.

Several of the company’s mineral rights are located adjacent to or near mineral rights that belong to a large publicly traded competitor company which has demonstrated through extensive drilling the presence of lithium deposits totaling over 100 million tons, according to its publicly available filings!

This is a Highly Attractive Location:

◼ Resource Potential to Support Large Scale Operations
✓ The Brazilian Geological Service (CPRM) suggested that the region has at least 45 lithium deposits
✓ Adjacent to operational lithium mines in the region such as Sigma Lithium and CBL

◼ Licensing Fast Track to Speed up Project Execution – Atlas with Permits in Place
✓ Minas Gerais government created a fast-track process, under the InvestMinas Program, to facilitate project development and allow for licensing to be issued quickly
✓ Mining friendly jurisdiction: 300+ operating mines in the state of Minas Gerais

◼ Favorable Infrastructure
✓ Access to abundant renewable & clean energy sources and highway roads directly connected to intercontinental ports to supply main markets

Recent exploration activities at both the company’s Salinas and the Clear Projects have yielded significant progress, and such development bodes well for ATLX’s strategy of securing as many high-quality deposit areas within LV as feasible.

A Big Neighbor

Atlas Lithium’s strategic holdings of 85 mineral rights across 468 km2 in Minas Gerais position it as the emerging force in Brazil’s Lithium Valley, with several properties adjacent to Sigma Lithium Corporation, the region’s established producer. Sigma’s current market capitalization of approximately $1.2 billion—approximately twelve times that of Atlas Lithium—demonstrates the extraordinary value potential in the region. As Atlas Lithium follows a similar development path in the same proven lithium district the company represents a compelling growth opportunity at its current market valuation. The success of Sigma Lithium in establishing large-scale lithium operations provides a clear blueprint for Atlas Lithium’s development trajectory in this world-class mining jurisdiction.

‍

NEWS

Atlas Lithium Subsidiary’s Iron Quadrangle Project on Track for Q4 2025 Revenues

Sep 2, 2025

Atlas Lithium’s Critical Minerals Subsidiary Delivers Exceptional Rare Earths Grades and Premium Graphite Concentrate in Initial Reporting

Aug 25, 2025

Atlas Lithium Reports Excellent Exploration Progress at 100%-Owned Salinas Project

Aug 18, 2025

Atlas Lithium’s Neves Project Completes Definitive Feasibility Study Estimating 145% IRR and 11-Month Payback

Aug 4, 2025

Atlas Lithium’s Critical Minerals Subsidiary Reports Strong Rare Earths, Titanium, and Graphite Results

Jul 24, 2025

Brazil Lithium & Critical Minerals Summit 2025 Launches with Record Participation and Global Momentum

Jun 5, 2025

Atlas Lithium’s Modular Processing Plant Arrives in Brazil, Achieving Critical Milestone Toward Production

Mar 10, 2025

Atlas Lithium Strengthens Position in Critical Minerals with Rare Earths, Titanium, Graphite, and Uranium Exposure

Mar 5, 2025

Atlas Lithium to Present at Fastmarkets Battery Raw Materials Shanghai 2025 Conference

Feb 10, 2025

Atlas Lithium’s Plant Is Now En Route to Brazil – Marking Major Milestone Towards Production

Feb 3, 2025

Atlas Lithium’s Processing Plant Prepares for Shipment to Brazil

Jan 21, 2025

Atlas Lithium Accelerates Production Readiness with Key Executive Appointments

Dec 30, 2024

Atlas Lithium Outlines Regional Growth Strategy

Nov 25, 2024

Atlas Lithium’s Neves Project Is Now Permitted

Oct 28, 2024

Atlas Lithium Advances Its Salinas Project

Oct 7, 2024

Atlas Lithium Progresses Towards Key Permitting

Sep 23, 2024

Atlas Lithium’s Progress: Processing Plant Readies For Shipment To Site

Aug 28, 2024

Atlas Lithium Recognized for Its Plant Design

Aug 27, 2024

Atlas Lithium’s Modular Lithium Processing Plant Readies for Brazil

Aug 22, 2024

All Eyes On Atlas Lithium As The US Assistant Secretary Of State For Energy Resources Visits The Company’s Headquarters In Brazil

Jul 26, 2024

‍

‍

MANAGEMENT

Marc Fogassa

Chairman & Chief Executive Officer

Marc Fogassa has been a director and our Chairman and Chief Executive Officer since 2012. He has extensive experience in venture capital and public company chief executive management. He has served on boards of directors of multiple private companies in various industries and has been invited to speak about investment issues, particularly as related to Brazil. Mr. Fogassa double majored at the Massachusetts Institute of Technology (M.I.T.), graduating with two Bachelor of Science degrees in 1990. He later graduated from the Harvard Medical School with a Doctor of Medicine degree in 1995 and also from the Harvard Business School with a Master of Business Administration degree in 1999 with Second-Year Honors. At Harvard Business School, he was Co-President of the Venture Capital and Private Equity Club. Mr. Fogassa was born in Brazil and is fluent in Portuguese and English. Mr. Fogassa is also the Chairman and Chief Executive Officer of Jupiter Gold Corporation and Chairman and Chief Executive Officer of Apollo Resources Corporation, two companies in which we own equity positions.

Tiago Miranda

CFO & Treasurer

Tiago Miranda is our Chief Financial Officer, Principal Accounting Officer, and Treasurer. From February 2024 until July 2024, Mr. Miranda was the Chief Financial Officer of Apollo Resources Corporation, a private company and a subsidiary of Atlas Lithium. In such capacity, Mr. Miranda managed all of Apollo Resources’ financial and administrative related processes, including treasury, accounting, tax, and financial planning and budgeting.

Previously, from May 2020 to December 2023, Mr. Miranda was the senior financial officer for the Brazilian operations of Horizonte Minerals Plc., a British publicly listed company with two nickel projects in Brazil. During his tenure, he successfully contributed to securing project financing of US$713 million for a ferronickel project and an additional $300 million Brazilian real credit facility with Banco da Amazônia. Between November 2019 to April 2020, Mr. Miranda held the position of Financial Controller for the Brazilian operations at Equinox Gold, a Canadian publicly listed gold producer.

From March 2008 to October 2019, Mr. Miranda served as the Controller of Ferrous Resources Ltd., an iron producer partially owned by Icahn Enterprises, a NYSE-listed company. He actively contributed to the development of company projects from exploration through construction and operation and was also heavily involved in Ferrous Resources’ US$550 million sale to Vale S/A, the largest Brazilian mining company.

From September 2005 to March 2008, Mr. Miranda was an auditor with Deloitte Touche Tohmatsu in Brazil. He has an undergraduate degree in Business Administration and Accounting, and a Master of Business Administration, both from IBMEC in Brazil. Mr. Miranda is fluent in Portuguese and English.

Eduardo Queiroz

Project Management Officer (PMO) & Vice President of Engineering

Eduardo Queiroz has served as Project Management Officer and Vice President of Engineering at Atlas Lithium since December 2024. He brings over 20 years of expertise in managing large-scale and complex mining projects, most recently as General Manager of Planning and Management at Bamin, a unit of Eurasian Resources Group. During his tenure at Bamin, he successfully led the strategic planning of several projects exceeding US$3 billion in value, including an integrated iron ore mining project that encompassed mining operations, processing plant, railway, and ocean port facilities.

Mr. Queiroz’s comprehensive experience includes engineering oversight, environmental compliance, risk management, and the implementation of cost-efficient operational strategies. His expertise in project implementation and management of Brazilian mining projects makes him instrumental in driving Atlas Lithium’s Neves Project toward revenue generation. He holds an MBA in Project Management from Fundação Getúlio Vargas and a degree in Civil Engineering from the Universidade Federal de Ouro Preto.

Igor Tkachenko

Vice President, Corporate Strategy

Igor Tkachenko has been our Vice President of Corporate Strategy since 2023. Igor Tkachenko, a Ukrainian-American and a US-trained physician, has served as a strategic advisor to us since 2021, lending his leadership talents and private sector experience to further the company’s mission to become a leading hard-rock lithium provider for the green energy transition. In 2022, Mr. Tkachenko began consulting for us as our Director of Strategic Development, overseeing the rapid expansion of our investor relations efforts. He participated in the design and execution of our organizational growth strategy that led to our successful up-listing to Nasdaq in January 2023. On the heels of this major milestone, Mr. Tkachenko transitioned from his academic role as a Clinical Assistant Professor to take on an executive position at Atlas Lithium and began serving as our Vice President of Corporate Strategy in 2023. His education includes a Bachelor of Science (Summa Cum Laude) and a Doctor of Medicine degrees.

SINCERELY,

DISCLAIMER

THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.

OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF TWENTY THOUSAND USD BY SIDEWAYS FREQUENCY LLC FOR A ONE DAY ATLX AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.

***Sponsored by LFG Equities Corp.

NeoVolta Enters Into Letter of Intent to Acquire Neubau Energy’s Next-Generation Battery Platform

NeoVolta Distributor Orders Top $3M in Single Quarter

NEOV has onboarded over 10% of Texas’s solar installers as NeoVolta Certified Dealers in a single quarter

NeoVolta Predicts Third Consecutive Record Quarter; Forecasts Over 225% Revenue Growth for Fiscal Year 2025

_________________________

Hello Everyone,

We have another brand new profile for you to research ahead of Tuesday’s session. This one is brand new to our members as this is our first time covering this emerging company.

Pull up NEOV immediately and put it at the top of your screen.

This one has closed green 7 of the last 8 and it is picking up momentum and gaining exposure every day. In the last 5-6 sessions we have seen interest pick up tremendously followed by positive price action. Quarterly revenues are approaching the $5 Million mark while we just saw 3 consecutive record setting quarters in a row.

NeoVolta is a leading innovator in energy storage solutions dedicated to advancing the future of clean energy. Founded to provide reliable, sustainable, and high-performance energy storage systems, the company has quickly established itself as a critical player in the industry. NeoVolta’s flagship products are designed to meet the growing demand for efficient energy management in residential and commercial applications. With a focus on cutting-edge technology and strategic partnerships, NeoVolta is committed to driving progress in renewable energy and enhancing how the world stores and uses power.

The energy storage solutions sector is hot right now because it sits at the intersection of renewable energy adoption, grid reliability, and electrification trends. Storage is the keystone of the clean energy transition. With that being said, the U.S. Inflation Reduction Act (IRA) provides big tax credits and incentives for battery storage. Europe, China, and other regions also subsidize grid-scale storage as part of their net-zero commitments. We are also seeing government mandates for carbon reduction make storage a must-have infrastructure investment, not optional.

NEOV’s products have garnered industry awards and acclaim for their unique Lithium Iron Phosphate (LiFePO₄) chemistry, prioritizing fire safety and longevity over traditional lithium-ion competitors.

Residential Storage: NV14 & NV24

The core of NeoVolta’s product line is the NV14 Energy Storage System—a fully integrated hybrid inverter and battery solution that commands attention for its robust features.

The NV14 system combines a high-efficiency 7.68 kW AC/DC inverter with a 14.4 kWh battery, capable of handling both on-grid and off-grid scenarios.

Its battery chemistry virtually eliminates thermal runaway risk, making it a safer choice for households concerned with fire hazards.

The NV14’s UL certification guarantees compliance with rigorous safety standards, while its NEMA3R-rated enclosure allows both indoor and outdoor installation.

Homeowners have praised NeoVolta’s NV14 for rapid installation (typically within one day), its reliability through power outages, and its seamless compatibility with solar systems and generators.

The NV14 can be expanded to 24 kWh using NeoVolta’s NV24 add-on, granting greater backup duration and the ability to power more household loads without additional inverters.

Notably, this solution lasts 50% longer than many lithium-ion batteries, supporting over 6,000 deep cycles and a service life exceeding 16 years, compared to only about 4,000 cycles for most competitors.

Commercial & Industrial Solutions

Expanding beyond residential energy needs, NeoVolta has developed modular solutions for commercial and industrial applications.

Their Battery Energy Storage Systems (BESS) scale up to 250 kW/430 kWh, offering advanced load management for businesses, schools, and microgrids.

These scalable units enable users to reduce demand charges, ensure operational continuity during outages, and optimize their utilization of solar energy.

Built on the same fire-safe chemistry, these systems validate NeoVolta’s commitment to sustainability and reliability.

NeoVolta Predicts Third Consecutive Record Quarter; Forecasts Over 225% Revenue Growth for Fiscal Year 2025

Triple-Digit Growth Highlights NeoVolta’s Expansion in U.S. Energy Storage Market

SAN DIEGO, July 16, 2025 (GLOBE NEWSWIRE) — NeoVolta Inc. (NASDAQ: NEOV), a U.S.-based energy technology company providing scalable energy storage solutions for resilient residential and commercial power infrastructure, today announced preliminary results for its fiscal fourth quarter, marking its third consecutive record-setting quarter. Estimated revenue for the quarter is approximately $5 million. Full-year revenue for fiscal 2025 is projected to more than triple compared to fiscal 2024.

This growth rate significantly exceeds the residential energy storage industry’s typical annual growth of approximately 20%, according to multiple industry research sources. NeoVolta’s expansion—approximately ten times the industry average—underscores accelerating demand for its American-assembled battery systems.

“Our third consecutive record quarter highlights NeoVolta’s ability to scale production and capture market share,” said Ardes Johnson, CEO of NeoVolta. “In a market where annual growth is typically sub 20%, our performance demonstrates clear product differentiation and operational momentum.”

Operational Highlights:

• Three consecutive record-setting quarters
• FY 2025 revenue projected to exceed 200% year-over-year growth
• Quarterly revenue approaching $5 million
• U.S.-based assembly supporting American homeowners seeking energy resilience and tax incentives

“We believe NeoVolta is strongly positioned to capitalize on growing demand for residential energy storage,” Johnson added. “With utility rates rising, grid reliability declining, and homeowner interest in American-assembled solutions increasing, we expect sustained demand as we expand partnerships and distribution channels.”

NeoVolta Unveils Its 250kW / 430kWh Commercial & Industrial BESS at RE+ 2025; Availability Beginning in Q4 2025

SAN DIEGO, Sept. 11, 2025 (GLOBE NEWSWIRE) — NeoVolta Inc. (NASDAQ: NEOV), a U.S.-based energy technology company delivering scalable storage, for resilient residential and commercial power infrastructure, today unveiled its first Commercial & Industrial (C&I) energy storage solution: the 250kW / 430kWh battery energy storage system (BESS). The new product can be seen at the company’s booth, no. V12313, at RE+ 2025 in Las Vegas.

The NeoVolta C&I BESS is designed to deliver powerful, scalable energy management for commercial properties, industrial sites, and microgrid applications. Built with the same safety-first approach and installer-centered design as NeoVolta’s residential systems, the C&I BESS offers businesses a path to energy independence, demand charge reduction, and backup power resilience.

Key features of the 250kW / 430kWh C&I BESS include:

• 250kW power capacity and 430kWh of usable energy
• Modular, scalable design for commercial deployments
• Integrated controls for demand management and time-of-use optimization
• Compatible with solar, generator, and grid-tied configurations
• Designed for both grid services and backup power applications

“Expanding into the C&I market is a natural evolution for NeoVolta and part of our ongoing commitment to serving the full spectrum of energy storage needs, from residential to large-scale commercial,” said Ardes Johnson, CEO of NeoVolta. “Our new BESS solution gives commercial customers the same trusted quality, safety, and flexibility that installers already know us for in the residential space.”

NeoVolta will begin accepting commercial project inquiries at RE+ 2025, with availability for installations beginning in Q4 2025. The C&I BESS will be sold through authorized NeoVolta distributors and directly for large-scale projects.

NeoVolta and Expion360 Announce LOI to Advance Battery Manufacturing and Product Design

SAN DIEGO, Dec. 11, 2024 (GLOBE NEWSWIRE) — NeoVolta Inc. (Nasdaq: NEOV) (“NeoVolta”), a leading innovator in energy storage solutions, is excited to announce the execution of a non-binding letter of intent (“LOI”) with Expion360 Inc. (Nasdaq: XPON) (“Expion360”), a renowned expert in battery design and engineering, and an industry leader in lithium-ion battery power storage solutions. ​The LOI provides the framework for a potential collaboration that aims to leverage the parties’ shared resources to engineer a state-of-the-art battery manufacturing facility and develop innovative lithium-ion battery cell and module product designs, marking a significant milestone in the production of American-made batteries.

If the parties proceed with a formal engagement under the LOI, Expion360 intends to contribute its expertise in design and engineering, while NeoVolta plans to provide the necessary capital and manpower. ​Together, the companies expect to bring high-performance, sustainable energy storage solutions to the market to address the growing demand for efficient energy management in both residential and commercial applications.

Recently NeoVolta completed phase one of its loan application for $250 million from the U.S. Department of Energy (DOE) Title 17 Loan Program (LPO), and has been approved to proceed with phase two, consisting of technical due diligence. To meet domestic content requirements for commercial grade Battery Electric Storage Systems (BESS) and other components, NeoVolta must establish a state-of-the-art manufacturing facility that can accommodate more than 150 high-paid employees. Domestic content requirements for the entire industry were codified in the bipartisan Inflation Reduction Act (IRA) in 2022, and President-elect Trump has continued to promote American production throughout his transition announcements.

“We are thrilled to join forces with Expion360. This collaboration aligns perfectly with our mission to drive progress in renewable energy and enhance how the world stores and uses power. By taking this initial step to combine our strengths, we are confident we can deliver cutting-edge energy storage solutions that meet the highest standards of performance and reliability,” said Ardes Johnson, CEO of NeoVolta.

“Partnering with NeoVolta is a significant step forward for Expion360. We believe our expertise in battery design and engineering, coupled with NeoVolta’s resources and commitment to innovation, will enable us to create exceptional products that will set new benchmarks in the industry. ​We look forward to seeing the impact of our collaboration on the future of clean energy,” said Brian Schaffner, CEO of Expion360.

The LOI underscores the commitment of both companies to advance the future of clean energy through innovation and collaboration. ​As they work together to bring their American-made batteries to fruition, NeoVolta and Expion360 plan to make a lasting impact on the energy storage industry.

About Expion360

Expion360 is an industry leader in premium lithium iron phosphate (LiFePO4) batteries and accessories for recreational vehicles and marine applications, with residential and industrial applications under development. On December 19, 2023, the Company announced its entrance into the home energy storage market with the introduction of two premium LiFePO4 battery storage systems that enable residential and small business customers to create their own stable micro-energy grid and lessen the impact of increasing power fluctuations and outages.

The Company’s lithium-ion batteries feature half the weight of standard lead-acid batteries while delivering three times the power and ten times the number of charging cycles. Expion360 batteries also feature better construction and reliability compared to other lithium-ion batteries on the market due to their superior design and quality materials. Specially reinforced, fiberglass-infused, premium ABS and solid mechanical connections help provide top performance and safety. With Expion360 batteries, adventurers can enjoy the most beautiful and remote places on Earth even longer.

The Company is headquartered in Redmond, Oregon. Expion360 lithium-ion batteries are available today through more than 300 dealers, wholesalers, private-label customers, and OEMs across the country. To learn more about the Company, visit Expion360.com.

NeoVolta Captures Texas Market Momentum with Record Installer Growth

Signs Over 10% of Statewide Installers in One Quarter; Solartek Deal Expands Distribution Footprint

SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) — NeoVolta Inc. (NASDAQ: NEOV), U.S.-based energy technology company delivering scalable storage for resilient residential and commercial power infrastructure, today announced unprecedented growth in Texas.

“Texas is a key market for us, and with new product introduction in the last quarter, we’ve onboarded over 10% of Texas’s solar installers as NeoVolta Certified Dealers,” said Ardes Johnson, CEO of NeoVolta. “This momentum reflects how strongly homeowners are seeking more control over their energy use and resilience during outages.”

Texas, now one of the fastest-growing battery storage markets in the U.S., surpassed 6,200 megawatts of installed capacity by the end of 2024. NeoVolta’s recent traction aligns with a statewide trend toward energy security in the face of rising costs and weather-driven grid stress.

To further support its reach, NeoVolta has formed a distribution partnership with Dallas-based Solartek Distributors, LLC, known for reliable delivery and a comprehensive portfolio of solar and storage equipment. Solartek’s strong local presence will help accelerate deployment and training for Texas-based installers.

“Partnering with NeoVolta is a natural fit as we support installers with leading-edge technology,” said Uros Ceglaj, CEO of Solartek Distributors. “Their growth speaks for itself — and we’re aligned with their mission to advance U.S.-made energy solutions.”

NEWS

NeoVolta Unveils Its 250kW / 430kWh Commercial & Industrial BESS at RE+ 2025; Availability Beginning in Q4 2025

3 days ago

NeoVolta Enters Into Letter of Intent to Acquire Neubau Energy’s Next-Generation Battery Platform

4 days ago

NeoVolta to Debut New NV16kW AC Hybrid Inverter with 24kW PV Input at RE+ 2025 in Las Vegas

Sep 5, 2025

NeoVolta Predicts Third Consecutive Record Quarter; Forecasts Over 225% Revenue Growth for Fiscal Year 2025

Jul 16, 2025

NeoVolta Distributor Orders Top $3M in Single Quarter

Jun 10, 2025

NeoVolta Sets New Sales Record in April, Surpassing Entire First Quarter in a Single Month

Apr 29, 2025

NeoVolta Captures Texas Market Momentum with Record Installer Growth

Apr 23, 2025

NeoVolta Highlights Virtual Peaker’s Announcement of Strategic Partnership for Smarter Energy Storage Integration

Apr 11, 2025

NeoVolta Anticipates Record Quarterly Sales, Surpassing $2 Million in Revenue – a Projected Increase of over 600% Year-over-Year

Mar 27, 2025

DELETED: NeoVolta (NEOV) $300M Loan Application Passes Phase 2 of Department of Energy Loan Program

Feb 25, 2025

‍

MANAGEMENT TEAM

Ardes Johnson

CEO

Ardes is the new Chief Executive Officer at NeoVolta. Mr. Johnson brings with him a wealth of experience and a proven track record of transformative leadership in the energy sector. As Director of Americas Sales and Marketing for Tesla’s Energy Products division, Johnson was instrumental in the development and success of Tesla’s energy storage solutions, where he and his team launched the partner channel program for the PowerWall and PowerPack products in the Utility, Residential and Commercial Markets.

Steve Bond

CFO & Director

Steve’s background lies in executive consulting for companies in the areas of finance, strategy, and revenue growth. He founded and grew his own regional CFO advisory firm for 7 years before joining NeoVolta, and graduated summa cum laude in finance at San Diego State University.

Michael Mendik

Chief Operating Officer

Michael is the COO and he oversees NeoVolta’s operations, including sales, marketing, product management, and customer service. He joined from GoodWe, where he served as Country Manager/General Manager for North America. His strategic leadership and ability to build top-performing teams have been instrumental in achieving significant market share and revenue growth.

John Hass

Director

John brings nearly three decades of power systems experience to the team. His career started at TEAL Electronics in 1994, and he’s currently the Chief Product Officer for Shoals Technologies. John also has a B.S. in Mechanical Engineering and a MBA from San Diego State University.

SINCERELY,

DISCLAIMER

THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.

OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF TWENTY THOUSAND USD BY LFG EQUITIES CORP FOR A ONE DAY NEOV AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.

‍